Aniridia

👪

Inheritance

1

Autosomal dominant HP:0000006

Aniridia is transmitted as an autosomal dominant trait with high penetrance and variable expressivity, and results from haploinsufficiency: one functional PAX6 allele is not enough. Roughly a third of probands represent de novo events, and a de novo case with a chromosomal deletion is the situation in which WAGR must be excluded.

Autosomal dominant inheritance

Show evidence (2 references)

PMID:24138039 SUPPORT Other

"Classic aniridia can be genetically defined as the presence of a PAX6 gene deletion or loss-of-function mutation that results in haploinsufficiency."

Establishes haploinsufficiency, rather than a dominant-negative or gain-of-function mechanism, as the basis of the dominant inheritance in classic aniridia.

PMID:20301534 SUPPORT Other

"Approximately two thirds of individuals diagnosed with PAX6 aniridia syndrome have an affected parent. Approximately one third of affected individuals have the disorder as the result of a de novo PAX6 genetic alteration."

GeneReviews supplies the inherited-versus-de-novo split stated in this entry's description, which was previously asserted without a citation. Evidence source is OTHER because GeneReviews is an expert-curated clinical synthesis rather than a primary study.

◆

Subtypes

5

Isolated (non-syndromic) aniridia MONDO:0007119

Aniridia caused by an intragenic PAX6 loss-of-function variant or by a deletion confined to PAX6 and its cis-regulatory region, without extraocular malignancy risk. This is the majority form. Within it, genotype modulates severity: missense variants, which retain partial PAX6 function, give the mildest phenotype, whereas whole-gene deletions and nonsense or frameshift variants abolish one allele outright.

Aniridia 1
Aniridia 2
Aniridia 3

Show evidence (1 reference)

PMID:34101622 SUPPORT Human Clinical

"Overall, the missense mutation subgroup had the mildest phenotype, and surgically naive eyes maintained better visual acuity."

Longitudinal cohort of 86 molecularly confirmed patients showing that residual PAX6 function stratifies severity within the isolated form.

WAGR syndrome (contiguous 11p13 deletion) MONDO:0008681

PAX6 hgnc:8620 WT1 hgnc:12796 Autosomal dominant inheritance

Aniridia arising as part of a contiguous gene deletion at 11p13 that removes WT1 as well as PAX6, producing Wilms tumour predisposition, genitourinary anomalies and intellectual disability alongside the ocular phenotype. Because the aniridia is the visible sign and often the presenting one, every child with apparently isolated sporadic aniridia requires molecular definition of the deletion breakpoints before renal tumour surveillance can be safely omitted.

Show evidence (1 reference)

PMID:33300417 SUPPORT BACKGROUND Human Clinical

"WAGR results from a contiguous gene deletion within the 11p13 region, encompassing the WT1 gene, often responsible for WT development, and the PAX6 gene, responsible for aniridia."

Defines the contiguous-deletion architecture that separates this subtype from the isolated form and locates the tumour risk in WT1 rather than in PAX6.

Aniridia 1 (intragenic PAX6 lesion) MONDO:0024507

PAX6 hgnc:8620 Autosomal dominant inheritance

Aniridia caused by a lesion within the PAX6 transcription unit itself: a loss-of-function variant, or a deletion of the gene, producing haploinsufficiency. This is the ordinary molecular form, and the one the sibling rows are defined against.

Show evidence (1 reference)

PMID:24138039 SUPPORT REVIEW SYNTHESIS Other

"Classic aniridia can be genetically defined as the presence of a PAX6 gene deletion or loss-of-function mutation that results in haploinsufficiency."

Defines the intragenic-lesion form this row names, as distinct from the cis-regulatory and trans-acting forms on the sibling rows.

Aniridia 2 (PAX6 cis-regulatory deletion in the ELP4 locus) MONDO:0014937

PAX6 hgnc:8620 ELP4 hgnc:1171 Autosomal dominant inheritance

Aniridia in which the PAX6 transcription unit is intact and the lesion removes cis-regulatory DNA downstream of it. Those control elements lie within introns of the neighbouring ELP4 gene, so the deletion is annotated against ELP4 while the gene whose expression fails is PAX6. ClinGen records coding loss of function in ELP4 as not expected to contribute to eye disease at all, which is what separates a host locus from a causal gene here.

Show evidence (3 references)

CGGV:assertion_095db206-85a6-491a-929c-bb4db8d1240a-2023-11-16T170000.000Z SUPPORT Other

"The mechanism of pathogenicity appears to be monoallelic disruption of enhancer elements located in the introns of ELP4 but required for efficient PAX6 transactivation during ocular development"

ClinGen locates the lesion in PAX6 enhancer elements that happen to sit in ELP4 introns, which is why PAX6 is bound as the gene whose expression fails, with ELP4 bound only as the host locus.

CGGV:assertion_095db206-85a6-491a-929c-bb4db8d1240a-2023-11-16T170000.000Z SUPPORT Other

"Please note that loss-of-function variants within the coding regions of ELP4 are not expected to contribute to eye disease"

Direct statement that ELP4 coding loss of function does not cause eye disease, so ELP4 is the host locus and not the causal gene.

PMID:11087823 SUPPORT Human Clinical

"We report two submicroscopic de novo deletions of 11p13 that cause aniridia but are located >11 kb from the 3' end of PAX6."

Patient deletions that preserve the PAX6 transcription unit, which is the defining feature of this row.

Aniridia 3 (TRIM44) MONDO:0014938

TRIM44 hgnc:19016 Autosomal dominant inheritance

A form reported in one four-generation Chinese pedigree in which a missense variant in TRIM44 segregated with aniridia, and overexpressed TRIM44 lowered PAX6 in a human lens epithelial cell line more strongly for the mutant than for the wild-type protein. The lesion is in TRIM44 coding sequence and acts in trans on PAX6, which makes it mechanistically unlike the cis-regulatory deletion on the Aniridia 2 row, although both reduce PAX6 expression and both MONDO and ClinGen file them under one parent concept. ClinGen grades the relationship Limited on the strength of a single study, so this row is recorded as a reported form rather than an established one.

Show evidence (4 references)

CGGV:assertion_c03ad7e1-74ea-4c47-b372-5beb8fbf4e97-2023-03-16T160000.000Z SUPPORT Other

ClinGen's grade for this gene-disease relationship, which is what stops the genetic row being typed CAUSATIVE.

CGGV:assertion_c03ad7e1-74ea-4c47-b372-5beb8fbf4e97-2023-03-16T160000.000Z SUPPORT Other

"There is only one published study reporting this gene-disease association to date, so there is limited but suggestive evidence to support the relationship between TRIM44 and ocular dysgenesis caused by defects in PAX6 regulation."

States the extent of the evidence base, which is the reason this row is described as a reported form.

CGGV:assertion_c03ad7e1-74ea-4c47-b372-5beb8fbf4e97-2023-03-16T160000.000Z SUPPORT Human Clinical

"In 7 affected members of 4-generation Chinese family with aniridia linked to chromosome 11p13, Zhang et al. (PMID: 26394807) identified a heterozygous missense variant, c.463G>A (p.Gly155Arg), in exon 1 of TRIM44"

The single pedigree behind this row, with the variant ClinGen scored.

+ 1 more reference

?

Discussions and Knowledge Gaps

1

Can renal tumour surveillance be safely discontinued in a child with sporadic aniridia once an intragenic PAX6 variant has been identified and a WT1-spanning deletion excluded?

KNOWLEDGE GAP aniridia_wt_surveillance_isolated_pax6

Attached to

pathophysiology#PAX6 Haploinsufficiency

Current practice rests on the assumption that Wilms tumour risk in aniridia is carried entirely by WT1 loss in the contiguous deletion, so identifying an intragenic PAX6 variant should release the child from years of ultrasound surveillance. A reported case of Wilms tumour in a patient with aniridia due to a heterozygous PAX6 nonsense variant and no other identifiable germline driver directly unsettles that assumption. Because the decision trades a real surveillance burden against a lethal but treatable malignancy, and because it is the only mortality-relevant decision in the management of aniridia, the question is worth marking explicitly rather than treating as settled.

Proposed experiments

Registry-scale tumour incidence in molecularly defined intragenic PAX6 aniridia

aniridia_intragenic_pax6_tumour_registry

Pool international aniridia registries to estimate Wilms tumour incidence specifically among patients with confirmed intragenic PAX6 variants and breakpoint-mapped exclusion of WT1 involvement, with power to detect an excess over population background.

⚙

Pathophysiology

9

Deletion of the PAX6 Downstream Regulatory Region

The two patients reported by Lauderdale et al. carry submicroscopic de novo deletions at 11p13 that start more than 11 kb beyond the PAX6 3' end and retain its transcription unit. These lesions affect the downstream regulatory landscape containing the ELP4-intronic DRR. Patient deletion boundaries differ; the enhancer-region annotation does not define one shared complete deletion or exclude contributions from other deleted genes.

Genetic context Variant type: deletion Genomic context: intron allele_type: de novo downstream deletions retaining the PAX6 transcription unit variant_origin: GERMLINE zygosity: HETEROZYGOUS

Affected regions (reference genome)

PAX6 downstream regulatory region (DRR) 11p13 enhancer

Within gene: ELP4 hgnc:1171

Cluster of PAX6-specific long-range control elements in ELP4 introns, downstream of PAX6. The named region identifies regulatory sequence within the larger patient deletions; it is not the entire deletion interval or a claim that ELP4 protein loss causes aniridia.

Downstream

Reduced PAX6 Expression after Downstream Regulatory Deletion Loss of downstream cis-regulatory DNA prevents normal expression from the intact PAX6 allele.

Show evidence (2 references)

PMID:11087823 SUPPORT Human Clinical

"We report two submicroscopic de novo deletions of 11p13 that cause aniridia but are located >11 kb from the 3' end of PAX6."

Defines the gene-intact downstream human deletion class.

PMID:17014839 SUPPORT BACKGROUND Model Organism

"Analysis of the region beyond this breakpoint using YAC transgenic mice, DNaseI hypersensitivity mapping and reporter transgenic assays revealed the presence of several putative cis-regulatory elements, including ones driving expression in lens and retina (Kleinjan et al., 2001). These elements..."

Summarizes earlier transgenic-mouse enhancer mapping and the human locus annotation placing the DRR within ELP4. This is background support for the enhancer host and target, not a new patient deletion measurement.

Reduced PAX6 Expression after Downstream Regulatory Deletion

Human-mouse retinoblastoma somatic-cell hybrids carrying the patient chromosomes express PAX6 from the normal homolog but not the deletion homolog. Separately, deletion of the DRR from a human PAX6 reporter YAC in transgenic mice removes retinal expression while lens expression remains at embryonic day E10.5. Together these experiments support loss of regulatory input to intact PAX6. They do not establish uniform loss across all tissues in the patients, so no all-tissue expression-loss category is assigned to these deletions.

PAX6 hgnc:8620

PAX6 gene expression GO:0010467 ↓ DECREASED

Downstream

PAX6 Haploinsufficiency Reduced expression from the deletion-bearing chromosome is inferred to lower functional PAX6 dosage in affected ocular tissues.

Show evidence (2 references)

PMID:11087823 SUPPORT In Vitro

"Using human x mouse retinoblastoma somatic cell hybrids, we show that PAX6 is transcribed only from the normal allele but not from the deleted chromosome 11 homolog."

Direct allele-specific expression evidence comes from somatic-cell hybrids, not patient embryonic eyes.

PMID:17014839 SUPPORT INDIRECT Model Organism

"Similarly at E10.5, when Y001 has strong expression in both lens and retina, Y001ΔDRR maintains lens expression but expression in the retina is completely lost"

The engineered human-locus reporter establishes different requirements for the DRR in retina and lens at E10.5; it does not imply preservation of lens expression at later developmental stages.

PAX6 Haploinsufficiency

Heterozygous coding loss-of-function variants, whole-gene deletions, and downstream regulatory deletions converge on insufficient PAX6 activity in ocular tissues. Regulatory deletions can reduce expression while retaining the PAX6 transcription unit; their effects need not be uniform across tissues. PAX6 is a paired-box and homeodomain transcription factor required for ocular development and maintenance.

PAX6 hgnc:8620

Camera-type eye development GO:0043010 ↓ DECREASED

DNA-binding transcription factor activity GO:0003700 ↓ DECREASED

Downstream

Failed Anterior Segment and Foveal Differentiation

Limbal Stem Cell Deficiency

Show evidence (1 reference)

PMID:34101622 SUPPORT Human Clinical

"Aniridia is most commonly caused by haploinsufficiency of the PAX6 gene, characterized by variable iris and foveal hypoplasia, nystagmus, cataracts, glaucoma, and aniridia-related keratopathy (ARK)."

Establishes PAX6 haploinsufficiency as the initiating lesion and lists the multi-tissue phenotype bundle it produces, which is what this node's downstream edges model.

Failed Anterior Segment and Foveal Differentiation

Reduced PAX6 dose during ocular morphogenesis leaves the periocular mesenchyme-derived structures of the anterior segment incompletely differentiated, and simultaneously arrests the specialization of the central retina. The iris stroma and its muscle fail to form beyond a rudimentary stump; the iridocorneal angle and trabecular meshwork are maldeveloped; the lens is prone to opacification; and the foveal pit, which requires postnatal displacement of inner retinal layers over a cone-only centre, never fully excavates. That the same lesion hits both the anterior segment and the fovea is why aniridia is a pan-ocular disease rather than an iris disease.

migratory cranial neural crest cell CL:0000008 trabecular meshwork cell CL:0002367

Iris morphogenesis GO:0061072 ↓ DECREASED Trabecular meshwork development GO:0002930 ↓ DECREASED Retina development in camera-type eye GO:0060041 ⚠ ABNORMAL

anterior segment of eyeball UBERON:0001801

Downstream

Maldeveloped Aqueous Outflow and Secondary Glaucoma

Congenital Visual Impairment with Nystagmus

Show evidence (2 references)

PMID:40892309 SUPPORT Other

"The main visible phenotypic characteristic is the partial or complete absence of the iris; however, foveal hypoplasia is a more frequent and reliable clinical sign."

Supports the dual anterior-and-posterior claim this node makes, and the specific point that the foveal component is the more consistent consequence of the PAX6 lesion than the iris component the disease is named for. Evidence source is OTHER because this is a consensus guideline review.

PMID:41936534 SUPPORT Other

"Anterior Segment Dysgenesis (ASD) encompasses a heterogeneous group of congenital ocular malformations resulting from disrupted differentiation of neural crest-derived tissues."

Places the anterior segment half of this node in the shared neural-crest differentiation mechanism the entry declares conformance to. Evidence source is OTHER because this is a review.

Limbal Stem Cell Deficiency

A distinct, postnatally progressive arm. PAX6 is required not only to build the cornea but to maintain the limbal epithelial stem cell niche that renews it throughout life. With one allele, the stem cell compartment is functionally deficient: single-cell profiling of Pax6-heterozygous mouse cornea shows an accumulation of stem-like and early transit-amplifying cells that fail to commit to a mature corneal epithelial fate. Chronic inflammation and ocular surface dryness compound the defect. This is why aniridia-associated keratopathy is the one feature of the disease that reliably worsens with age rather than being fixed at birth.

limbal epithelial stem cell of cornea CL:4033093 corneal epithelial cell CL:0000575

Epithelial cell differentiation GO:0030855 ↓ DECREASED Cornea development in camera-type eye GO:0061303 ⚠ ABNORMAL

cornea UBERON:0000964

Experimental models

Patient-derived iPSC corneal organoid model of aniridia-associated keratopathy ORGANOID The organoid provides a human, patient-genotype platform for interrogating corneal epithelial differentiation, which is the process this node asserts is defective.

Animal models

Pax6 heterozygous mouse Mouse recapitulates Reproduces the human haploinsufficient genotype and the corneal stem-cell-commitment defect, in the tissue where the human disease progresses.

Downstream

Aniridia-Associated Keratopathy

Show evidence (2 references)

PMID:41590604 SUPPORT Model Organism

"Our single cell transcriptome of the limbus and cornea of Pax6 het mice indicates that AAK may be due to the increase of dysfunctional stem/eTACs with defects in committing to a corneal epithelial cell fate and differentiation."

Provides the cellular mechanism this node asserts - a failure of commitment rather than a loss of stem cells - in the heterozygous model that matches the human genotype.

PMID:42048350 SUPPORT In Vitro

"Congenital aniridia, a rare disorder caused by PAX6 haploinsufficiency, is characterized by progressive, vision-threatening aniridia-associated keratopathy (AAK) with limbal epithelial dysfunction and chronic inflammation."

Supports the progressive, inflammation-associated character of the limbal arm that distinguishes it from the fixed developmental defects.

Aniridia-Associated Keratopathy

The clinical expression of limbal failure: conjunctival epithelium progressively invades the corneal surface, bringing vessels with it, and the cornea becomes vascularized, opaque and unstable. It begins peripherally and advances centrally over decades, so a patient whose acuity was limited by foveal hypoplasia in childhood may lose further vision to the cornea in adulthood. Keratopathy is the feature that most often prompts surgery, and the one whose surgery most often fails, because a transplanted cornea placed on a limbally deficient surface is re-invaded.

corneal epithelial cell CL:0000575

cornea UBERON:0000964

Show evidence (1 reference)

PMID:24138039 SUPPORT Other

"Aniridia-associated keratopathy (AAK) is a progressive and potentially debilitating problem affecting aniridic patients."

Establishes the progressive and sight-threatening character of this consequence node. Evidence source is OTHER because this is a review.

Maldeveloped Aqueous Outflow and Secondary Glaucoma

The maldeveloped iridocorneal angle limits aqueous outflow, and in many patients the rudimentary iris stump progressively rotates forward to occlude what angle there is. Intraocular pressure rises, typically in later childhood or adolescence rather than infancy, and glaucomatous optic neuropathy follows. Glaucoma affects roughly a fifth of eyes in longitudinal cohorts and is, with keratopathy, one of the two acquired threats that make aniridia a lifelong surveillance diagnosis rather than a static malformation.

trabecular meshwork cell CL:0002367

Trabecular meshwork development GO:0002930 ↓ DECREASED

eye trabecular meshwork UBERON:0005969

Show evidence (2 references)

PMID:34101622 SUPPORT Human Clinical

"Cataracts were diagnosed in 70.3%, glaucoma in 20.6%, and ARK in 68.6% of eyes."

Quantifies glaucoma frequency in a molecularly confirmed longitudinal cohort, supporting the roughly one-in-five figure this node states.

PMID:41936534 SUPPORT Other

"These disorders frequently lead to developmental glaucoma, a major cause of childhood blindness."

Supports treating the glaucoma of aniridia as the shared terminal consequence of anterior segment dysgenesis rather than an incidental comorbidity. Evidence source is OTHER because this is a review.

Congenital Visual Impairment with Nystagmus

Foveal hypoplasia deprives the developing visual system of a high-acuity fixation locus, so acuity is subnormal from birth and infantile nystagmus develops as a consequence of that sensory deficit rather than as an independent motor abnormality. The absent or deficient iris compounds disability by removing the aperture stop, producing the photophobia and glare that patients frequently rank above acuity loss as their dominant symptom. Because the sensory deficit is congenital and structural, acuity in aniridia does not improve with refractive correction.

Visual perception GO:0007601 ↓ DECREASED

Show evidence (1 reference)

PMID:40892309 SUPPORT Other

"The main ocular symptoms experienced by those with congenital aniridia are photophobia, glare, low visual acuity, dryness/irritation of the ocular surface and nystagmus."

Documents the symptom set this node asserts, and specifically that photophobia and glare rank with acuity loss in the patient-experienced burden. Evidence source is OTHER because this is a consensus guideline.

WT1 Haploinsufficiency in the Contiguous 11p13 Deletion

WT1 lies in the same 11p13 interval as PAX6, so a contiguous deletion encompassing both converts isolated aniridia into WAGR spectrum disorder. WT1 encodes a zinc finger DNA-binding protein that acts as a transcriptional activator or repressor depending on context, and the variants reported for Wilms tumour type 1 are predominantly loss of function. Wilms tumours are thought to arise from abnormally persistent embryonal cells in nephrogenic rests, and in this form one WT1 allele is already absent from that tissue. This is the arm of the deletion that carries the tumour risk; the ocular phenotype is assigned to PAX6.

WT1 hgnc:12796

WT1 transcriptional regulation of nephrogenic tissue GO:0003700 ↓ DECREASED

Downstream

Wilms Tumour Loss of the WT1 allele carried on the deleted chromosome is what puts a child with contiguous-deletion aniridia at risk of nephroblastoma, and is why renal surveillance turns on whether the deletion breakpoints spare WT1. The germline loss raises risk rather than producing the tumour: a somatic second hit in a nephrogenic rest is required, and the cited sentence states the risk relation rather than the intervening steps.

Show evidence (4 references)

PMID:41818601 SUPPORT DIRECT REVIEW SYNTHESIS Other

"The diagnosis of WAGR spectrum disorder is established in a proband with suggestive findings and a deletion of chromosome 11p13 that includes the genes WT1 and PAX6 identified by molecular genetic testing."

The GeneReviews chapter for the contiguous-deletion form defines it by a deletion spanning both genes, which is the lesion this node describes.

CGGV:assertion_65010002-ff97-4dc0-a89f-6c77abf0982a-2020-07-30T205501.047Z SUPPORT DIRECT Other

"In summary, loss of function variants in WT1 are definitively associated with autosomal dominant Wilms tumor type 1."

ClinGen's Definitive grade for WT1 loss of function and dominant Wilms tumour, which is the gene-disease claim this node rests on.

CGGV:assertion_65010002-ff97-4dc0-a89f-6c77abf0982a-2020-07-30T205501.047Z SUPPORT DIRECT Other

"The WT1 gene encodes a zinc finger DNA-binding protein that acts as a transcriptional activator or repressor depending on the cellular or chromosomal context"

Source for the molecular function bound on this node, and for the description's account of what the lost allele does.

+ 1 more reference

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

13

Cardiovascular 1

Ocular Surface Dryness Keratoconjunctivitis sicca HP:0001097

Show evidence (1 reference)

PMID:40892309 SUPPORT Other

"The main ocular symptoms experienced by those with congenital aniridia are photophobia, glare, low visual acuity, dryness/irritation of the ocular surface and nystagmus."

Names ocular surface dryness and irritation among the main symptoms.

Endocrine 1

Type 2 Diabetes Mellitus Type II diabetes mellitus HP:0005978

Show evidence (1 reference)

PMID:34101622 SUPPORT Human Clinical

"Systemic evaluation identified type 2 diabetes in 12.8% of the study group, which is twice the UK prevalence."

Quantifies the excess directly. No frequency band is asserted because the claim of interest is the excess over background, not the raw proportion.

Eye 9

Aniridia HP:0000526

Show evidence (1 reference)

PMID:24138039 SUPPORT Other

"Aniridia classically presents with a bilateral congenital absence or malformation of the irides, foveal hypoplasia, and nystagmus, and patients tend to develop visually significant pre-senile cataracts and keratopathy."

Establishes bilateral iris absence or malformation as the defining presenting feature. No frequency band is asserted: this source states a definition rather than a proportion, and the guideline literature reports that iris absence is LESS consistent than foveal hypoplasia, which is banded FREQUENT here on a measured 75%. Claiming a higher band for the iris finding than for the foveal one would contradict that source.

Foveal Hypoplasia FREQUENT Hypoplasia of the fovea HP:0007750

Show evidence (1 reference)

PMID:34101622 SUPPORT Human Clinical

"Nystagmus was recorded in 87.2% of the eyes, and foveal hypoplasia was found in 75%."

Quantifies foveal hypoplasia at 75% of 172 eyes, supporting the FREQUENT band (80-30%).

Nystagmus VERY_FREQUENT HP:0000639

Show evidence (1 reference)

PMID:34101622 SUPPORT Human Clinical

"Nystagmus was recorded in 87.2% of the eyes, and foveal hypoplasia was found in 75%."

87.2% of eyes places nystagmus in the VERY_FREQUENT band (99-80%).

Cataract FREQUENT HP:0000518

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:34101622 SUPPORT Human Clinical

"Cataracts were diagnosed in 70.3%, glaucoma in 20.6%, and ARK in 68.6% of eyes."

70.3% of eyes places cataract in the FREQUENT band (80-30%).

Aniridia-Associated Keratopathy FREQUENT Abnormal cornea morphology HP:0000481

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:34101622 SUPPORT Human Clinical

"Cataracts were diagnosed in 70.3%, glaucoma in 20.6%, and ARK in 68.6% of eyes."

68.6% of eyes affected by aniridia-related keratopathy, placing it in the FREQUENT band (30-79%). The phenotype is bound to the broad corneal term because the 68.6% figure was measured for keratopathy as a whole; binding it to a narrower feature such as corneal neovascularization would apply a frequency to something this source did not measure.

Glaucoma OCCASIONAL HP:0000501

Show evidence (1 reference)

PMID:34101622 SUPPORT Human Clinical

"Cataracts were diagnosed in 70.3%, glaucoma in 20.6%, and ARK in 68.6% of eyes."

20.6% of eyes places glaucoma in the OCCASIONAL band (29-5%).

Photophobia HP:0000613

Show evidence (1 reference)

PMID:40892309 SUPPORT Other

"The main ocular symptoms experienced by those with congenital aniridia are photophobia, glare, low visual acuity, dryness/irritation of the ocular surface and nystagmus."

Names photophobia first among the main patient-experienced symptoms. No frequency band is asserted because this source reports symptom prominence, not a proportion.

Reduced Visual Acuity HP:0007663

Show evidence (1 reference)

PMID:40892309 SUPPORT Other

"The main ocular symptoms experienced by those with congenital aniridia are photophobia, glare, low visual acuity, dryness/irritation of the ocular surface and nystagmus."

Documents low visual acuity as a core feature. Evidence source is OTHER because this is a consensus guideline review.

Optic Nerve Hypoplasia HP:0000609

Show evidence (1 reference)

PMID:40892309 SUPPORT Other

"Other ocular comorbidities are associated with the disease, such as cataract, keratopathy and optic nerve hypoplasia."

Lists optic nerve hypoplasia among the recognized ocular comorbidities of congenital aniridia.

Genitourinary 1

Wilms Tumour Nephroblastoma HP:0002667

Show evidence (1 reference)

PMID:33300417 SUPPORT BACKGROUND Human Clinical

"Aniridia, a pan-ocular disease resulting from iris hypoplasia, is thought to increase the risk for WT development if their genetic alteration spans both the WT1 and the PAX6 genes on 11p13."

Ties the tumour risk specifically to deletions spanning WT1, which is what restricts this phenotype to the WAGR subtype.

Nervous System 1

Intellectual Disability HP:0001249

Show evidence (1 reference)

PMID:34876316 SUPPORT Human Clinical

"Wilms' tumor, aniridia, genitourinary anomalies, and mental retardation (WAGR) syndrome is a contiguous gene deletion syndrome caused by a de novo deletion including the 11p13 region."

Establishes intellectual disability as a defining component of the contiguous deletion syndrome rather than of PAX6-related aniridia itself.

🧬

Genetic Associations

4

PAX6 (Heterozygous loss-of-function variant or whole-gene deletion)

Gene: PAX6 hgnc:8620 gene page relationship_type: CAUSATIVE

Show evidence (1 reference)

PMID:24138039 SUPPORT Other

"Variants of aniridia, which include a condition previously referred to as autosomal dominant keratitis, are likely due to PAX6 mutations that lead to partial loss of PAX6 function."

Supports the allelic-series claim that residual PAX6 function produces milder, sometimes differently named phenotypes.

PAX6 downstream regulatory region (Deletion of cis-regulatory DNA with an intact PAX6 transcription unit)

relationship_type: CAUSATIVE

Affected regions (reference genome)

PAX6 downstream regulatory region (DRR) 11p13 enhancer

Within gene: ELP4 hgnc:1171

PAX6-specific control elements within ELP4 introns, downstream of their target gene.

Show evidence (2 references)

PMID:11087823 SUPPORT Human Clinical

"We report two submicroscopic de novo deletions of 11p13 that cause aniridia but are located >11 kb from the 3' end of PAX6."

Supports aniridia caused by downstream deletions rather than PAX6 coding loss.

PMID:17014839 SUPPORT BACKGROUND Model Organism

"Analysis of the region beyond this breakpoint using YAC transgenic mice, DNaseI hypersensitivity mapping and reporter transgenic assays revealed the presence of several putative cis-regulatory elements, including ones driving expression in lens and retina (Kleinjan et al., 2001). These elements..."

Background description of transgenic-mouse enhancer mapping and the human locus places the named DRR elements within ELP4 introns, without making ELP4 the regulatory target.

Variants (1)

Lauderdale et al. PAX6 downstream deletions (cases 1 and 2)

Gene: ELP4 hgnc:1171 Regulatory target: PAX6 hgnc:8620 deletion

Genomic context: intron

Affected regions (reference genome)

PAX6 downstream regulatory region (DRR) 11p13 enhancer

Within gene: ELP4 hgnc:1171

The affected enhancer cluster is one component of the larger downstream deletions.

Two de novo submicroscopic deletions in the sporadic aniridia cases reported by Lauderdale et al. retain PAX6 and lie more than 11 kb beyond its 3' end. Their expression defect was assayed in human-mouse somatic-cell hybrids. These are two distinct alleles, not one recurrent deletion; the regional annotation does not assign common nucleotide breakpoints.

Functional effects

PAX6 cis-regulatory control ENHANCER

PAX6 transcription was absent from the deletion-bearing chromosome in somatic-cell hybrids. This assay does not establish all-tissue loss of expression in the patients or isolate the contribution of every individual enhancer within the deleted region.

Mechanism: Deletion of downstream positive regulatory elements

Show evidence (3 references)

PMID:11087823 SUPPORT Human Clinical

"We report two submicroscopic de novo deletions of 11p13 that cause aniridia but are located >11 kb from the 3' end of PAX6."

The two sporadic patient deletions preserve the PAX6 transcription unit.

PMID:11087823 SUPPORT In Vitro

"PAX6 is transcribed only from the normal allele but not from the deleted chromosome 11 homolog."

Allele-specific transcription was tested in human-mouse retinoblastoma somatic-cell hybrids.

PMID:17014839 SUPPORT BACKGROUND Model Organism

"Analysis of the region beyond this breakpoint using YAC transgenic mice, DNaseI hypersensitivity mapping and reporter transgenic assays revealed the presence of several putative cis-regulatory elements, including ones driving expression in lens and retina (Kleinjan et al., 2001). These elements..."

Summarizes earlier transgenic-mouse enhancer mapping and the human locus annotation supporting ELP4 as the DRR host, separate from PAX6 as the regulatory target. It does not resolve these patients' deletion breakpoints.

WT1 (Heterozygous loss within a contiguous 11p13 deletion)

Gene: WT1 hgnc:12796 gene page relationship_type: CAUSATIVE

Show evidence (1 reference)

PMID:33300417 SUPPORT BACKGROUND Human Clinical

"WAGR results from a contiguous gene deletion within the 11p13 region, encompassing the WT1 gene, often responsible for WT development, and the PAX6 gene, responsible for aniridia."

Assigns the tumour risk to WT1 and the ocular phenotype to PAX6 within one deletion, which is the basis for separating this gene's contribution to the WAGR subtype.

TRIM44 (Heterozygous missense variant acting in trans on PAX6 expression)

Gene: TRIM44 hgnc:19016 relationship_type: UNKNOWN

Show evidence (4 references)

CGGV:assertion_c03ad7e1-74ea-4c47-b372-5beb8fbf4e97-2023-03-16T160000.000Z SUPPORT Other

"TRIM44 was mapped to 11p13 in a study (PMID:10568747) searching for genes in a region of chromosome 11 associated with WAGR syndrome (Wilms tumor-aniridia-genital anomalies-retardation)."

Source for the locus and for how the gene came to attention in aniridia.

CGGV:assertion_c03ad7e1-74ea-4c47-b372-5beb8fbf4e97-2023-03-16T160000.000Z SUPPORT Other

"There is only one published study reporting this gene-disease association to date, so there is limited but suggestive evidence to support the relationship between TRIM44 and ocular dysgenesis caused by defects in PAX6 regulation."

ClinGen's own statement of how thin the evidence base is, which is the reason for the UNKNOWN typing on this row.

CGGV:assertion_c03ad7e1-74ea-4c47-b372-5beb8fbf4e97-2023-03-16T160000.000Z SUPPORT Human Clinical

"In 7 affected members of 4-generation Chinese family with aniridia linked to chromosome 11p13, Zhang et al. (PMID: 26394807) identified a heterozygous missense variant, c.463G>A (p.Gly155Arg), in exon 1 of TRIM44"

The single pedigree behind this row, with the variant ClinGen scored.

+ 1 more reference

💊

Medical Actions

5

Topical Intraocular Pressure-Lowering Pharmacotherapy

Action: Pharmacotherapy NCIT:C15986

Agent: prostaglandin analogue (e.g. latanoprost) CHEBI:6384 topical beta-blocker (e.g. timolol) CHEBI:39465

Platform: Small molecule

First-line medical management of the secondary glaucoma, using topical agents such as prostaglandin analogues, beta-blockers and carbonic anhydrase inhibitors. Glaucoma in aniridia responds less predictably than primary open-angle glaucoma because the outflow pathway is structurally maldeveloped rather than merely obstructed, so lifelong pressure surveillance is required from diagnosis.

Mechanism Target:

INHIBITS Maldeveloped Aqueous Outflow and Secondary Glaucoma — Lowering intraocular pressure targets the consequence of the maldeveloped outflow pathway; it does not correct the developmental defect, which is why control is imperfect and surveillance permanent.

Show evidence (1 reference)

PMID:40892309 SUPPORT Other

"Management and follow-up of patients with congenital aniridia can be challenging due to the lack of effective therapeutic options and the complexity of ocular manifestations and outcomes."

The European guideline states plainly that effective therapeutic options are lacking. Marked PARTIAL because it supports the management framing while explicitly not asserting efficacy.

Glaucoma Surgery for Medically Uncontrolled Intraocular Pressure

Action: Ophthalmologic Surgical Procedure NCIT:C15331

Platform: Surgery

Angle or filtering surgery, or a glaucoma drainage device, when topical therapy fails to control pressure. Separated from the medical arm because it is a different modality with a different risk profile, and because surgically naive eyes in the longitudinal cohort maintained better visual acuity - so the decision to operate is itself consequential rather than a simple escalation.

Mechanism Target:

INHIBITS Maldeveloped Aqueous Outflow and Secondary Glaucoma — Surgical drainage bypasses the maldeveloped outflow pathway rather than correcting it, which is why pressure control remains imperfect and surveillance permanent.

Show evidence (1 reference)

PMID:34101622 SUPPORT Human Clinical

"Prevalence, age of diagnosis and surgical intervention, and need for surgical intervention varied among mutation groups."

Establishes that surgical intervention is part of the management of this disease and that the need for it is genotype-dependent. Marked PARTIAL because the cohort reports variation in surgical need rather than demonstrating surgical efficacy.

Limbal Stem Cell Replacement and Keratoprosthesis

Action: Ophthalmologic Surgical Procedure NCIT:C15331

Platform: Surgery

Surgical management of advanced keratopathy. Because the corneal opacity is driven by a deficient stem cell niche rather than by the cornea itself, plain penetrating keratoplasty is re-conjunctivalized; the options are to replace the limbal stem cells by keratolimbal allograft, with or without subsequent keratoplasty, or to bypass the surface entirely with a Boston type 1 keratoprosthesis.

Mechanism Target:

RESTORES Limbal Stem Cell Deficiency — Keratolimbal allograft aims to restore the deficient stem cell compartment itself, which is why it is directed at this node rather than at the keratopathy it produces.

Show evidence (1 reference)

PMID:24138039 SUPPORT Other

"The current treatments for AAK are to replace the limbal stem cells through keratolimbal allograft (KLAL) with or without subsequent keratoplasty for visual rehabilitation, or to implant a Boston type 1 keratoprosthesis."

States that the therapeutic target is the limbal stem cell compartment, supporting the mechanism link this treatment declares.

Show evidence (1 reference)

PMID:24138039 SUPPORT Other

"The current treatments for AAK are to replace the limbal stem cells through keratolimbal allograft (KLAL) with or without subsequent keratoplasty for visual rehabilitation, or to implant a Boston type 1 keratoprosthesis."

Enumerates the current surgical options for aniridia-associated keratopathy. Evidence source is OTHER because this is a review.

Renal Tumour Surveillance in Contiguous Deletion Aniridia

Action: Supportive Care NCIT:C15747

Platform: Other

Serial renal ultrasonography for children with sporadic aniridia until the molecular lesion is shown not to involve WT1. This is the one intervention in aniridia that alters mortality rather than vision, and it is why molecular diagnosis in a sporadic case is urgent. Applies to the WAGR (contiguous 11p13 deletion) subtype.

Show evidence (1 reference)

PMID:33300417 SUPPORT Human Clinical

"Isolated mutations in PAX6 previously have not been associated with increased risk of WT development case raises the question of if surveillance for WT should be continued in patients with aniridia with an isolated PAX6 mutation identified."

Supports surveillance as the standard for deletion-associated aniridia while documenting the open question this case raises about whether an identified isolated PAX6 variant is sufficient to stop it. Marked PARTIAL because it is a single case that unsettles rather than confirms practice.

Genetic Counselling and Molecular Diagnosis

Action: Genetic Counseling NCIT:C15240

Platform: Other

Determination of the causative lesion - intragenic PAX6 variant versus contiguous 11p13 deletion - drives both tumour surveillance and reproductive counselling for a dominant condition with high penetrance and a substantial de novo rate.

Show evidence (1 reference)

PMID:24138039 SUPPORT Other

"Classic aniridia can be genetically defined as the presence of a PAX6 gene deletion or loss-of-function mutation that results in haploinsufficiency."

Supports the genetic definition on which counselling and the deletion-versus-intragenic distinction rest. Evidence source is OTHER because this is a review.

🧫

Experimental Models

1

Patient-derived iPSC corneal organoid model of aniridia-associated keratopathy ORGANOID

Three-dimensional corneal organoids differentiated from induced pluripotent stem cells of aniridia patients, generating corneal epithelial-like cells in a self-assembled tissue that reproduces the native corneal microenvironment. Provides a human genotype-matched system for the limbal arm of the disease, complementing the Pax6-heterozygous mouse.

Publication

PMID:42612147

Pathograph links

Limbal Stem Cell Deficiency measures fidelity: moderate The organoid provides a human, patient-genotype platform for interrogating corneal epithelial differentiation, which is the process this node asserts is defective.

Limitations: Organoids lack the limbal niche vasculature, tear film, innervation and chronic inflammatory environment in which aniridia-associated keratopathy actually progresses, so they can model the differentiation defect but not the decades-long clinical progression it drives.

Show evidence (1 reference)

PMID:42612147 SUPPORT In Vitro

"Our protocol involves the stepwise differentiation of iPSCs into corneal epithelial-like cells within self-assembled three-dimensional organoids, which mimic the native corneal microenvironment."

Establishes that the model produces the cell type whose differentiation this mechanism node concerns.

🐁

Animal Models

1

Pax6 heterozygous mouse

The standard genetic model of aniridia-associated keratopathy, matching the human haploinsufficient genotype. Single-cell RNA sequencing of its cornea and limbus identified an accumulation of quiescent limbal stem cell-like and early transit-amplifying cells that fail to commit to a corneal epithelial fate.

Species

Mouse

Genotype

Pax6 heterozygous (Pax6+/-)

Publication

PMID:41590604

Pathograph links

Limbal Stem Cell Deficiency recapitulates fidelity: moderate Reproduces the human haploinsufficient genotype and the corneal stem-cell-commitment defect, in the tissue where the human disease progresses.

Limitations: Mouse and human corneal limbal anatomy differ, and the mouse does not develop the decades-long conjunctivalization and vascularization that define the human keratopathy endpoint.

Readouts

Expression of corneal epithelial fate and differentiation genes in early transit-amplifying cells

Direction: DECREASED

Interpretation: Molecular correlate of the failed commitment this node asserts.

Show evidence (1 reference)

PMID:41590604 SUPPORT Model Organism

"The Pax6 deficiency inhibited the expression of genes involved in cell proliferation in the eTAC-like cluster as well as the expression of genes related to corneal epithelial cell fate and differentiation compared with WT mice."

Reports the measurement and its direction directly.

Show evidence (1 reference)

PMID:41590604 SUPPORT Model Organism

"Aniridia, driven by PAX6 mutations, causes aniridia-associated keratopathy (AAK), a progressive condition linked to limbal stem cell deficiency."

States the human mechanism the model is used to interrogate, supporting treating this model as informative for this node.

{ }

Source YAML

click to show

name: Aniridia
creation_date: "2026-08-22T00:00:00Z"
category: Mendelian
description: >
  Aniridia is a congenital, bilateral, pan-ocular malformation caused in most
  cases by haploinsufficiency of PAX6, the dose-sensitive transcription factor
  that governs eye development at 11p13. The name is a misnomer twice over. The
  iris is rarely wholly absent - partial hypoplasia is common - and the iris is
  not the most reliable sign: foveal hypoplasia is present more often, and is
  what limits acuity from birth. What the PAX6 lesion actually produces is a
  bundle of anterior and posterior segment defects that share one origin,
  progressing lifelong: nystagmus and foveal hypoplasia from infancy, cataract
  and glaucoma through childhood and adolescence, and aniridia-associated
  keratopathy from limbal stem cell deficiency, which opacifies and
  vascularizes the cornea in adulthood. About two thirds of cases are inherited
  as an autosomal dominant trait and one third arise de novo. When the causative
  lesion is a contiguous 11p13 deletion extending into WT1 rather than an
  intragenic PAX6 variant, the child has WAGR syndrome and carries a high risk
  of Wilms tumour, which makes determining the molecular lesion urgent rather
  than merely confirmatory.
disease_term:
  preferred_term: aniridia
  term:
    id: MONDO:0019172
    label: aniridia
synonyms:
- congenital aniridia
- PAX6-related aniridia
- iris hypoplasia
- aplasia of iris
parents:
- Ophthalmological Disease
- Anterior Segment Dysgenesis
inheritance:
- name: Autosomal dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >
    Aniridia is transmitted as an autosomal dominant trait with high penetrance
    and variable expressivity, and results from haploinsufficiency: one
    functional PAX6 allele is not enough. Roughly a third of probands represent
    de novo events, and a de novo case with a chromosomal deletion is the
    situation in which WAGR must be excluded.
  evidence:
  - reference: PMID:24138039
    reference_title: "A review of the clinical and genetic aspects of aniridia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Classic aniridia can be genetically defined as the presence of a PAX6 gene deletion or loss-of-function mutation that results in haploinsufficiency."
    explanation: >
      Establishes haploinsufficiency, rather than a dominant-negative or
      gain-of-function mechanism, as the basis of the dominant inheritance in
      classic aniridia.
  - reference: PMID:20301534
    reference_title: "PAX6 Aniridia Syndrome."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Approximately two thirds of individuals diagnosed with PAX6 aniridia syndrome have an affected parent. Approximately one third of affected individuals have the disorder as the result of a de novo PAX6 genetic alteration."
    explanation: >
      GeneReviews supplies the inherited-versus-de-novo split stated in this
      entry's description, which was previously asserted without a citation.
      Evidence source is OTHER because GeneReviews is an expert-curated clinical
      synthesis rather than a primary study.
has_subtypes:
- name: Isolated aniridia
  display_name: Isolated (non-syndromic) aniridia
  children:
  - Aniridia 1
  - Aniridia 2
  - Aniridia 3
  subtype_term:
    preferred_term: isolated aniridia
    term:
      id: MONDO:0007119
      label: isolated aniridia
  description: >
    Aniridia caused by an intragenic PAX6 loss-of-function variant or by a
    deletion confined to PAX6 and its cis-regulatory region, without extraocular
    malignancy risk. This is the majority form. Within it, genotype modulates
    severity: missense variants, which retain partial PAX6 function, give the
    mildest phenotype, whereas whole-gene deletions and nonsense or frameshift
    variants abolish one allele outright.
  evidence:
  - reference: PMID:34101622
    reference_title: "Longitudinal genotype-phenotype analysis in 86 patients with PAX6-related aniridia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Overall, the missense mutation subgroup had the mildest phenotype, and surgically naive eyes maintained better visual acuity."
    explanation: >
      Longitudinal cohort of 86 molecularly confirmed patients showing that
      residual PAX6 function stratifies severity within the isolated form.
- name: WAGR
  display_name: WAGR syndrome (contiguous 11p13 deletion)
  genes:
  - preferred_term: PAX6
    term:
      id: hgnc:8620
      label: PAX6
  - preferred_term: WT1
    term:
      id: hgnc:12796
      label: WT1
  inheritance:
  - name: Autosomal dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
    description: >-
      Typically caused by a de novo 11p13 deletion; rarely an unaffected parent
      carries a predisposing chromosome rearrangement.
    evidence:
    - reference: PMID:41818601
      reference_title: WAGR Spectrum Disorder.
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: "WAGR spectrum disorder is an autosomal dominant disorder typically caused by a de novo 11p13 deletion. Rarely, an unaffected parent of a proband with WAGR spectrum disorder has a predisposing chromosome rearrangement."
      explanation: >-
        The GeneReviews chapter states the inheritance mode, the de novo origin of
        the deletion, and the rare parental rearrangement.
  subtype_term:
    preferred_term: WAGR syndrome
    term:
      id: MONDO:0008681
      label: WAGR syndrome
  description: >
    Aniridia arising as part of a contiguous gene deletion at 11p13 that removes
    WT1 as well as PAX6, producing Wilms tumour predisposition, genitourinary
    anomalies and intellectual disability alongside the ocular phenotype.
    Because the aniridia is the visible sign and often the presenting one, every
    child with apparently isolated sporadic aniridia requires molecular
    definition of the deletion breakpoints before renal tumour surveillance can
    be safely omitted.
  evidence:
  - reference: PMID:33300417
    reference_title: "A rare case of an isolated PAX6 mutation, aniridia, and Wilms tumor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "WAGR results from a contiguous gene deletion within the 11p13 region, encompassing the WT1 gene, often responsible for WT development, and the PAX6 gene, responsible for aniridia."
    explanation: >
      Defines the contiguous-deletion architecture that separates this subtype
      from the isolated form and locates the tumour risk in WT1 rather than in
      PAX6.
- name: Aniridia 1
  display_name: Aniridia 1 (intragenic PAX6 lesion)
  subtype_term:
    preferred_term: aniridia 1
    term:
      id: MONDO:0024507
      label: aniridia 1
  description: >-
    Aniridia caused by a lesion within the PAX6 transcription unit itself: a
    loss-of-function variant, or a deletion of the gene, producing
    haploinsufficiency. This is the ordinary molecular form, and the one the
    sibling rows are defined against.
  genes:
  - preferred_term: PAX6
    term:
      id: hgnc:8620
      label: PAX6
  inheritance:
  - name: Autosomal dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  evidence:
  - reference: PMID:24138039
    reference_title: "A review of the clinical and genetic aspects of aniridia."
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "Classic aniridia can be genetically defined as the presence of a PAX6 gene deletion or loss-of-function mutation that results in haploinsufficiency."
    explanation: >-
      Defines the intragenic-lesion form this row names, as distinct from the
      cis-regulatory and trans-acting forms on the sibling rows.
- name: Aniridia 2
  display_name: Aniridia 2 (PAX6 cis-regulatory deletion in the ELP4 locus)
  subtype_term:
    preferred_term: aniridia 2
    term:
      id: MONDO:0014937
      label: aniridia 2
  description: >-
    Aniridia in which the PAX6 transcription unit is intact and the lesion
    removes cis-regulatory DNA downstream of it. Those control elements lie
    within introns of the neighbouring ELP4 gene, so the deletion is annotated
    against ELP4 while the gene whose expression fails is PAX6. ClinGen records
    coding loss of function in ELP4 as not expected to contribute to eye disease
    at all, which is what separates a host locus from a causal gene here.
  genes:
  - preferred_term: PAX6
    term:
      id: hgnc:8620
      label: PAX6
  - preferred_term: ELP4
    term:
      id: hgnc:1171
      label: ELP4
  inheritance:
  - name: Autosomal dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  evidence:
  - reference: CGGV:assertion_095db206-85a6-491a-929c-bb4db8d1240a-2023-11-16T170000.000Z
    reference_title: "ELP4 / ocular dysgenesis caused by defects in PAX6 regulation (Moderate)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The mechanism of pathogenicity appears to be monoallelic disruption of enhancer elements located in the introns of ELP4 but required for efficient PAX6 transactivation during ocular development"
    explanation: >-
      ClinGen locates the lesion in PAX6 enhancer elements that happen to sit in
      ELP4 introns, which is why PAX6 is bound as the gene whose expression
      fails, with ELP4 bound only as the host locus.
  - reference: CGGV:assertion_095db206-85a6-491a-929c-bb4db8d1240a-2023-11-16T170000.000Z
    reference_title: "ELP4 / ocular dysgenesis caused by defects in PAX6 regulation (Moderate)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Please note that loss-of-function variants within the coding regions of ELP4 are not expected to contribute to eye disease"
    explanation: >-
      Direct statement that ELP4 coding loss of function does not cause eye
      disease, so ELP4 is the host locus and not the causal gene.
  - reference: PMID:11087823
    reference_title: "3' deletions cause aniridia by preventing PAX6 gene expression."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report two submicroscopic de novo deletions of 11p13 that cause
      aniridia but are located >11 kb from the 3' end of PAX6.
    explanation: >-
      Patient deletions that preserve the PAX6 transcription unit, which is the
      defining feature of this row.
  review_notes: >-
    Both genes are bound, and they stand in different relations to the disease.
    MONDO's OWL causal-gene axiom for MONDO:0014937 is hgnc:1171 ELP4, and
    ClinGen curates an ELP4 gene-disease relationship at Moderate, against
    MONDO:0700246 "ocular dysgenesis caused by defects in PAX6 regulation"
    rather than against this class. Both nonetheless place the lesion in PAX6
    enhancer elements that lie inside ELP4 introns, and ClinGen adds that ELP4
    coding loss of function is not expected to cause eye disease. So ELP4 is the
    host locus of the deleted regulatory DNA, recorded structurally as
    affected_regions.within_gene on the PAX6 downstream regulatory region entry
    in the genetic section, and PAX6 is the gene whose expression fails.
- name: Aniridia 3
  display_name: Aniridia 3 (TRIM44)
  subtype_term:
    preferred_term: aniridia 3
    term:
      id: MONDO:0014938
      label: aniridia 3
  description: >-
    A form reported in one four-generation Chinese pedigree in which a missense
    variant in TRIM44 segregated with aniridia, and overexpressed TRIM44 lowered
    PAX6 in a human lens epithelial cell line more strongly for the mutant than
    for the wild-type protein. The lesion is in TRIM44 coding sequence and acts
    in trans on PAX6, which makes it mechanistically unlike the cis-regulatory
    deletion on the Aniridia 2 row, although both reduce PAX6 expression and both
    MONDO and ClinGen file them under one parent concept. ClinGen grades the
    relationship Limited on the strength of a single study, so this row is
    recorded as a reported form rather than an established one.
  genes:
  - preferred_term: TRIM44
    term:
      id: hgnc:19016
      label: TRIM44
  inheritance:
  - name: Autosomal dominant
    inheritance_term:
      preferred_term: Autosomal dominant inheritance
      term:
        id: HP:0000006
        label: Autosomal dominant inheritance
  evidence:
  - reference: CGGV:assertion_c03ad7e1-74ea-4c47-b372-5beb8fbf4e97-2023-03-16T160000.000Z
    reference_title: "TRIM44 / aniridia 3 (Limited)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TRIM44 | HGNC:19016 | aniridia 3 | MONDO:0014938 | AD | Limited"
    explanation: >-
      ClinGen's grade for this gene-disease relationship, which is what stops the
      genetic row being typed CAUSATIVE.
  - reference: CGGV:assertion_c03ad7e1-74ea-4c47-b372-5beb8fbf4e97-2023-03-16T160000.000Z
    reference_title: "TRIM44 / aniridia 3 (Limited)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "There is only one published study reporting this gene-disease association to date, so there is limited but suggestive evidence to support the relationship between TRIM44 and ocular dysgenesis caused by defects in PAX6 regulation."
    explanation: >-
      States the extent of the evidence base, which is the reason this row is
      described as a reported form.
  - reference: CGGV:assertion_c03ad7e1-74ea-4c47-b372-5beb8fbf4e97-2023-03-16T160000.000Z
    reference_title: "TRIM44 / aniridia 3 (Limited)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In 7 affected members of 4-generation Chinese family with aniridia linked to chromosome 11p13, Zhang et al. (PMID: 26394807) identified a heterozygous missense variant, c.463G>A (p.Gly155Arg), in exon 1 of TRIM44"
    explanation: >-
      The single pedigree behind this row, with the variant ClinGen scored.
  - reference: PMID:26394807
    reference_title: Variants in TRIM44 Cause Aniridia by Impairing PAX6 Expression.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Instead, we found that overexpression of TRIM44 significantly reduced the expression of PAX6 in human lens epithelial cells, and the p.G155R mutant exhibited much stronger effect than the wildtype form."
    explanation: >-
      The cell-line experiment behind the trans-repression mechanism this row
      describes.
pathophysiology:
- name: Deletion of the PAX6 Downstream Regulatory Region
  biological_scale: MOLECULAR
  role: trigger
  genetic_context:
    variant_type: deletion
    genomic_contexts:
    - intron
    affected_regions:
    - name: PAX6 downstream regulatory region (DRR)
      chromosomal_region: 11p13
      regulatory_element_type: ENHANCER
      within_gene:
        preferred_term: ELP4
        term:
          id: hgnc:1171
          label: ELP4
      description: >-
        Cluster of PAX6-specific long-range control elements in ELP4 introns,
        downstream of PAX6. The named region identifies regulatory sequence
        within the larger patient deletions; it is not the entire deletion
        interval or a claim that ELP4 protein loss causes aniridia.
    zygosity: HETEROZYGOUS
    variant_origin: GERMLINE
    allele_type: de novo downstream deletions retaining the PAX6 transcription unit
  description: >-
    The two patients reported by Lauderdale et al. carry submicroscopic de novo
    deletions at 11p13 that start more than 11 kb beyond the PAX6 3' end and
    retain its transcription unit. These lesions affect the downstream
    regulatory landscape containing the ELP4-intronic DRR. Patient deletion
    boundaries differ; the enhancer-region annotation does not define one
    shared complete deletion or exclude contributions from other deleted genes.
  evidence:
  - reference: PMID:11087823
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report two submicroscopic de novo deletions of 11p13 that cause aniridia
      but are located >11 kb from the 3' end of PAX6.
    explanation: Defines the gene-intact downstream human deletion class.
  - reference: PMID:17014839
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: BACKGROUND
    snippet: >-
      Analysis of the region beyond this breakpoint using YAC transgenic mice,
      DNaseI hypersensitivity mapping and reporter transgenic assays revealed
      the presence of several putative cis-regulatory elements, including ones
      driving expression in lens and retina (Kleinjan et al., 2001). These
      elements reside within introns of the adjacent, ubiquitously expressed
      ELP4 gene, but are nevertheless thought to be PAX6-specific long-range
      control elements (Kleinjan et al., 2002).
    explanation: >-
      Summarizes earlier transgenic-mouse enhancer mapping and the human
      locus annotation placing the DRR within ELP4. This is background
      support for the enhancer host and target, not a new patient deletion
      measurement.
  downstream:
  - target: Reduced PAX6 Expression after Downstream Regulatory Deletion
    causal_link_type: DIRECT
    description: Loss of downstream cis-regulatory DNA prevents normal expression from the intact PAX6 allele.
    evidence:
    - reference: PMID:11087823
      reference_title: "3' deletions cause aniridia by preventing PAX6 gene expression."
      supports: SUPPORT
      evidence_source: IN_VITRO
      directness: INDIRECT
      snippet: >-
        Using human x mouse retinoblastoma somatic cell hybrids, we show that
        PAX6 is transcribed only from the normal allele but not from the deleted
        chromosome 11 homolog.
      explanation: >-
        The deletion-to-expression relationship is demonstrated for patient
        chromosomes in somatic-cell hybrids. Its transfer to developing
        human ocular tissues is indirect.
- name: Reduced PAX6 Expression after Downstream Regulatory Deletion
  biological_scale: MOLECULAR
  description: >-
    Human-mouse retinoblastoma somatic-cell hybrids carrying the patient
    chromosomes express PAX6 from the normal homolog but not the deletion
    homolog. Separately, deletion of the DRR from a human PAX6 reporter YAC in
    transgenic mice removes retinal expression while lens expression remains
    at embryonic day E10.5.
    Together these experiments support loss of regulatory input to intact
    PAX6. They do not establish uniform loss across all tissues in the patients,
    so no all-tissue expression-loss category is assigned to these deletions.
  genes:
  - preferred_term: PAX6
    term:
      id: hgnc:8620
      label: PAX6
  biological_processes:
  - preferred_term: PAX6 gene expression
    term:
      id: GO:0010467
      label: gene expression
    modifier: DECREASED
  evidence:
  - reference: PMID:11087823
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Using human x mouse retinoblastoma somatic cell hybrids, we show that
      PAX6 is transcribed only from the normal allele but not from the deleted
      chromosome 11 homolog.
    explanation: Direct allele-specific expression evidence comes from somatic-cell hybrids, not patient embryonic eyes.
  - reference: PMID:17014839
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: INDIRECT
    snippet: >-
      Similarly at E10.5, when Y001 has strong expression in both lens and
      retina, Y001ΔDRR maintains lens expression but expression in the retina
      is completely lost
    explanation: >-
      The engineered human-locus reporter establishes different requirements
      for the DRR in retina and lens at E10.5; it does not imply preservation
      of lens expression at later developmental stages.
  downstream:
  - target: PAX6 Haploinsufficiency
    causal_link_type: DIRECT
    description: >-
      Reduced expression from the deletion-bearing chromosome is inferred to
      lower functional PAX6 dosage in affected ocular tissues.
    evidence:
    - reference: PMID:11087823
      reference_title: "3' deletions cause aniridia by preventing PAX6 gene expression."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        The clinical manifestations are indistinguishable from cases with
        chain-terminating mutations in the coding region.
      explanation: >-
        The similarity to coding-null aniridia supports convergence on PAX6
        insufficiency. Together with the somatic-cell-hybrid transcription
        assay, it supports the dosage mechanism without measuring protein
        abundance in the patients' developing eyes.
- name: PAX6 Haploinsufficiency
  description: >
    Heterozygous coding loss-of-function variants, whole-gene deletions, and
    downstream regulatory deletions converge on insufficient PAX6 activity
    in ocular tissues. Regulatory deletions can reduce expression while
    retaining the PAX6 transcription unit; their effects need not be uniform
    across tissues. PAX6 is a paired-box and homeodomain transcription factor
    required for ocular development and maintenance.
  role: convergence
  biological_scale: MOLECULAR
  genes:
  - preferred_term: PAX6
    term:
      id: hgnc:8620
      label: PAX6
  molecular_functions:
  - preferred_term: DNA-binding transcription factor activity
    term:
      id: GO:0003700
      label: DNA-binding transcription factor activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: Camera-type eye development
    term:
      id: GO:0043010
      label: camera-type eye development
    modifier: DECREASED
  conforms_to: "anterior_segment_dysgenesis#Anterior Segment Developmental Regulator Defect"
  evidence:
  - reference: PMID:34101622
    reference_title: "Longitudinal genotype-phenotype analysis in 86 patients with PAX6-related aniridia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Aniridia is most commonly caused by haploinsufficiency of the PAX6 gene, characterized by variable iris and foveal hypoplasia, nystagmus, cataracts, glaucoma, and aniridia-related keratopathy (ARK)."
    explanation: >
      Establishes PAX6 haploinsufficiency as the initiating lesion and lists the
      multi-tissue phenotype bundle it produces, which is what this node's
      downstream edges model.
  downstream:
  - target: Failed Anterior Segment and Foveal Differentiation
    causal_link_type: DIRECT
  - target: Limbal Stem Cell Deficiency
    causal_link_type: DIRECT

- name: Failed Anterior Segment and Foveal Differentiation
  description: >
    Reduced PAX6 dose during ocular morphogenesis leaves the periocular
    mesenchyme-derived structures of the anterior segment incompletely
    differentiated, and simultaneously arrests the specialization of the central
    retina. The iris stroma and its muscle fail to form beyond a rudimentary
    stump; the iridocorneal angle and trabecular meshwork are maldeveloped; the
    lens is prone to opacification; and the foveal pit, which requires postnatal
    displacement of inner retinal layers over a cone-only centre, never fully
    excavates. That the same lesion hits both the anterior segment and the fovea
    is why aniridia is a pan-ocular disease rather than an iris disease.
  role: central_effector
  biological_scale: TISSUE
  cell_types:
  - preferred_term: migratory cranial neural crest cell
    term:
      id: CL:0000008
      label: migratory cranial neural crest cell
  - preferred_term: trabecular meshwork cell
    term:
      id: CL:0002367
      label: trabecular meshwork cell
  biological_processes:
  - preferred_term: Iris morphogenesis
    term:
      id: GO:0061072
      label: iris morphogenesis
    modifier: DECREASED
  - preferred_term: Trabecular meshwork development
    term:
      id: GO:0002930
      label: trabecular meshwork development
    modifier: DECREASED
  - preferred_term: Retina development in camera-type eye
    term:
      id: GO:0060041
      label: retina development in camera-type eye
    modifier: ABNORMAL
  locations:
  - preferred_term: anterior segment of eyeball
    term:
      id: UBERON:0001801
      label: anterior segment of eyeball
  conforms_to: "anterior_segment_dysgenesis#Failed Differentiation and Separation of Anterior Segment Tissues"
  evidence:
  - reference: PMID:40892309
    reference_title: "Congenital aniridia: European COST action ANIRIDIA-NET guidelines for diagnosis, management and care."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The main visible phenotypic characteristic is the partial or complete absence of the iris; however, foveal hypoplasia is a more frequent and reliable clinical sign."
    explanation: >
      Supports the dual anterior-and-posterior claim this node makes, and the
      specific point that the foveal component is the more consistent
      consequence of the PAX6 lesion than the iris component the disease is
      named for. Evidence source is OTHER because this is a consensus guideline
      review.
  - reference: PMID:41936534
    reference_title: "Integrating clinical and genetic insights in anterior segment dysgenesis with glaucoma: A contemporary review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Anterior Segment Dysgenesis (ASD) encompasses a heterogeneous group of congenital ocular malformations resulting from disrupted differentiation of neural crest-derived tissues."
    explanation: >
      Places the anterior segment half of this node in the shared
      neural-crest differentiation mechanism the entry declares conformance to.
      Evidence source is OTHER because this is a review.
  downstream:
  - target: Maldeveloped Aqueous Outflow and Secondary Glaucoma
    causal_link_type: DIRECT
  - target: Congenital Visual Impairment with Nystagmus
    causal_link_type: DIRECT

- name: Limbal Stem Cell Deficiency
  description: >
    A distinct, postnatally progressive arm. PAX6 is required not only to build
    the cornea but to maintain the limbal epithelial stem cell niche that
    renews it throughout life. With one allele, the stem cell compartment is
    functionally deficient: single-cell profiling of Pax6-heterozygous mouse
    cornea shows an accumulation of stem-like and early transit-amplifying cells
    that fail to commit to a mature corneal epithelial fate. Chronic inflammation
    and ocular surface dryness compound the defect. This is why
    aniridia-associated keratopathy is the one feature of the disease that
    reliably worsens with age rather than being fixed at birth.
  role: effector
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: limbal epithelial stem cell of cornea
    term:
      id: CL:4033093
      label: limbal epithelial stem cell of cornea
  - preferred_term: corneal epithelial cell
    term:
      id: CL:0000575
      label: corneal epithelial cell
  biological_processes:
  - preferred_term: Epithelial cell differentiation
    term:
      id: GO:0030855
      label: epithelial cell differentiation
    modifier: DECREASED
  - preferred_term: Cornea development in camera-type eye
    term:
      id: GO:0061303
      label: cornea development in camera-type eye
    modifier: ABNORMAL
  locations:
  - preferred_term: cornea
    term:
      id: UBERON:0000964
      label: cornea
  evidence:
  - reference: PMID:41590604
    reference_title: "PAX6 Deficiency Compromises the Ability of Limbal Epithelial Stem Cells to Properly Differentiate Into Mature Corneal Epithelial Cells."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our single cell transcriptome of the limbus and cornea of Pax6 het mice indicates that AAK may be due to the increase of dysfunctional stem/eTACs with defects in committing to a corneal epithelial cell fate and differentiation."
    explanation: >
      Provides the cellular mechanism this node asserts - a failure of
      commitment rather than a loss of stem cells - in the heterozygous model
      that matches the human genotype.
  - reference: PMID:42048350
    reference_title: "Fatty acid-binding protein 5 (FABP5) modulates limbal epithelial cell homeostasis by regulating the expression of key genes under both normal and inflammatory conditions, in vitro."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Congenital aniridia, a rare disorder caused by PAX6 haploinsufficiency, is characterized by progressive, vision-threatening aniridia-associated keratopathy (AAK) with limbal epithelial dysfunction and chronic inflammation."
    explanation: >
      Supports the progressive, inflammation-associated character of the limbal
      arm that distinguishes it from the fixed developmental defects.
  downstream:
  - target: Aniridia-Associated Keratopathy
    causal_link_type: DIRECT

- name: Aniridia-Associated Keratopathy
  description: >
    The clinical expression of limbal failure: conjunctival epithelium
    progressively invades the corneal surface, bringing vessels with it, and the
    cornea becomes vascularized, opaque and unstable. It begins peripherally and
    advances centrally over decades, so a patient whose acuity was limited by
    foveal hypoplasia in childhood may lose further vision to the cornea in
    adulthood. Keratopathy is the feature that most often prompts surgery, and
    the one whose surgery most often fails, because a transplanted cornea placed
    on a limbally deficient surface is re-invaded.
  role: consequence
  biological_scale: TISSUE
  cell_types:
  - preferred_term: corneal epithelial cell
    term:
      id: CL:0000575
      label: corneal epithelial cell
  locations:
  - preferred_term: cornea
    term:
      id: UBERON:0000964
      label: cornea
  evidence:
  - reference: PMID:24138039
    reference_title: "A review of the clinical and genetic aspects of aniridia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Aniridia-associated keratopathy (AAK) is a progressive and potentially debilitating problem affecting aniridic patients."
    explanation: >
      Establishes the progressive and sight-threatening character of this
      consequence node. Evidence source is OTHER because this is a review.

- name: Maldeveloped Aqueous Outflow and Secondary Glaucoma
  description: >
    The maldeveloped iridocorneal angle limits aqueous outflow, and in many
    patients the rudimentary iris stump progressively rotates forward to occlude
    what angle there is. Intraocular pressure rises, typically in later childhood
    or adolescence rather than infancy, and glaucomatous optic neuropathy
    follows. Glaucoma affects roughly a fifth of eyes in longitudinal cohorts
    and is, with keratopathy, one of the two acquired threats that make aniridia
    a lifelong surveillance diagnosis rather than a static malformation.
  role: consequence
  biological_scale: ORGANISM
  cell_types:
  - preferred_term: trabecular meshwork cell
    term:
      id: CL:0002367
      label: trabecular meshwork cell
  biological_processes:
  - preferred_term: Trabecular meshwork development
    term:
      id: GO:0002930
      label: trabecular meshwork development
    modifier: DECREASED
  locations:
  - preferred_term: eye trabecular meshwork
    term:
      id: UBERON:0005969
      label: eye trabecular meshwork
  conforms_to: "anterior_segment_dysgenesis#Maldeveloped Aqueous Outflow Pathway and Developmental Glaucoma"
  evidence:
  - reference: PMID:34101622
    reference_title: "Longitudinal genotype-phenotype analysis in 86 patients with PAX6-related aniridia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cataracts were diagnosed in 70.3%, glaucoma in 20.6%, and ARK in 68.6% of eyes."
    explanation: >
      Quantifies glaucoma frequency in a molecularly confirmed longitudinal
      cohort, supporting the roughly one-in-five figure this node states.
  - reference: PMID:41936534
    reference_title: "Integrating clinical and genetic insights in anterior segment dysgenesis with glaucoma: A contemporary review."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These disorders frequently lead to developmental glaucoma, a major cause of childhood blindness."
    explanation: >
      Supports treating the glaucoma of aniridia as the shared terminal
      consequence of anterior segment dysgenesis rather than an incidental
      comorbidity. Evidence source is OTHER because this is a review.

- name: Congenital Visual Impairment with Nystagmus
  description: >
    Foveal hypoplasia deprives the developing visual system of a high-acuity
    fixation locus, so acuity is subnormal from birth and infantile nystagmus
    develops as a consequence of that sensory deficit rather than as an
    independent motor abnormality. The absent or deficient iris compounds
    disability by removing the aperture stop, producing the photophobia and
    glare that patients frequently rank above acuity loss as their dominant
    symptom. Because the sensory deficit is congenital and structural, acuity in
    aniridia does not improve with refractive correction.
  role: consequence
  biological_scale: ORGANISM
  biological_processes:
  - preferred_term: Visual perception
    term:
      id: GO:0007601
      label: visual perception
    modifier: DECREASED
  evidence:
  - reference: PMID:40892309
    reference_title: "Congenital aniridia: European COST action ANIRIDIA-NET guidelines for diagnosis, management and care."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The main ocular symptoms experienced by those with congenital aniridia are photophobia, glare, low visual acuity, dryness/irritation of the ocular surface and nystagmus."
    explanation: >
      Documents the symptom set this node asserts, and specifically that
      photophobia and glare rank with acuity loss in the patient-experienced
      burden. Evidence source is OTHER because this is a consensus guideline.
- name: WT1 Haploinsufficiency in the Contiguous 11p13 Deletion
  biological_scale: MOLECULAR
  description: >-
    WT1 lies in the same 11p13 interval as PAX6, so a contiguous deletion
    encompassing both converts isolated aniridia into WAGR spectrum disorder. WT1
    encodes a zinc finger DNA-binding protein that acts as a transcriptional
    activator or repressor depending on context, and the variants reported for
    Wilms tumour type 1 are predominantly loss of function. Wilms tumours are
    thought to arise from abnormally persistent embryonal cells in nephrogenic
    rests, and in this form one WT1 allele is already absent from that tissue.
    This is the arm of the deletion that carries the tumour risk; the ocular
    phenotype is assigned to PAX6.
  genes:
  - preferred_term: WT1
    term:
      id: hgnc:12796
      label: WT1
  molecular_functions:
  - preferred_term: WT1 transcriptional regulation of nephrogenic tissue
    modifier: DECREASED
    term:
      id: GO:0003700
      label: DNA-binding transcription factor activity
  evidence:
  - reference: PMID:41818601
    reference_title: WAGR Spectrum Disorder.
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: "The diagnosis of WAGR spectrum disorder is established in a proband with suggestive findings and a deletion of chromosome 11p13 that includes the genes WT1 and PAX6 identified by molecular genetic testing."
    explanation: >-
      The GeneReviews chapter for the contiguous-deletion form defines it by a
      deletion spanning both genes, which is the lesion this node describes.
  - reference: CGGV:assertion_65010002-ff97-4dc0-a89f-6c77abf0982a-2020-07-30T205501.047Z
    reference_title: "WT1 / Wilms tumor 1 (Definitive)"
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    snippet: "In summary, loss of function variants in WT1 are definitively associated with autosomal dominant Wilms tumor type 1."
    explanation: >-
      ClinGen's Definitive grade for WT1 loss of function and dominant Wilms
      tumour, which is the gene-disease claim this node rests on.
  - reference: CGGV:assertion_65010002-ff97-4dc0-a89f-6c77abf0982a-2020-07-30T205501.047Z
    reference_title: "WT1 / Wilms tumor 1 (Definitive)"
    supports: SUPPORT
    directness: DIRECT
    evidence_source: OTHER
    snippet: "The WT1 gene encodes a zinc finger DNA-binding protein that acts as a transcriptional activator or repressor depending on the cellular or chromosomal context"
    explanation: >-
      Source for the molecular function bound on this node, and for the
      description's account of what the lost allele does.
  - reference: CGGV:assertion_65010002-ff97-4dc0-a89f-6c77abf0982a-2020-07-30T205501.047Z
    reference_title: "WT1 / Wilms tumor 1 (Definitive)"
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: OTHER
    snippet: "Wilms tumours are thought to develop from abnormally persistent embryonal cells within nephrogenic rests"
    explanation: >-
      Source for the nephrogenic-rest substrate named in the description. Stated
      as the field's working model rather than as a measurement, so the link to
      this node's WT1 claim is inferential.
  downstream:
  - target: Wilms Tumour
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Loss of the WT1 allele carried on the deleted chromosome is what puts a
      child with contiguous-deletion aniridia at risk of nephroblastoma, and is
      why renal surveillance turns on whether the deletion breakpoints spare WT1.
      The germline loss raises risk rather than producing the tumour: a somatic
      second hit in a nephrogenic rest is required, and the cited sentence states
      the risk relation rather than the intervening steps.
    evidence:
    - reference: PMID:33300417
      reference_title: "A rare case of an isolated PAX6 mutation, aniridia, and Wilms tumor."
      supports: SUPPORT
      directness: DIRECT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      snippet: "Aniridia, a pan-ocular disease resulting from iris hypoplasia, is thought to increase the risk for WT development if their genetic alteration spans both the WT1 and the PAX6 genes on 11p13."
      explanation: >-
        Ties the tumour risk to deletions spanning WT1. Quoted from this report's
        introduction: its own proband carried an isolated PAX6 nonsense variant
        rather than a contiguous deletion.
phenotypes:
- category: Ocular
  name: Aniridia
  description: >
    Partial or complete bilateral absence of the iris, the eponymous sign.
    Complete absence is less common than a hypoplastic rudimentary stump
    visible on gonioscopy.
  phenotype_term:
    preferred_term: Aniridia
    term:
      id: HP:0000526
      label: Aniridia
  evidence:
  - reference: PMID:24138039
    reference_title: "A review of the clinical and genetic aspects of aniridia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Aniridia classically presents with a bilateral congenital absence or malformation of the irides, foveal hypoplasia, and nystagmus, and patients tend to develop visually significant pre-senile cataracts and keratopathy."
    explanation: >
      Establishes bilateral iris absence or malformation as the defining
      presenting feature. No frequency band is asserted: this source states a
      definition rather than a proportion, and the guideline literature reports
      that iris absence is LESS consistent than foveal hypoplasia, which is
      banded FREQUENT here on a measured 75%. Claiming a higher band for the
      iris finding than for the foveal one would contradict that source.
- category: Ocular
  name: Foveal Hypoplasia
  description: >
    Arrested foveal development with persistence of inner retinal layers over
    the foveal centre, detectable on optical coherence tomography. It is the
    principal determinant of the acuity ceiling and is more consistently present
    than iris absence.
  phenotype_term:
    preferred_term: Hypoplasia of the fovea
    term:
      id: HP:0007750
      label: Hypoplasia of the fovea
  frequency: FREQUENT
  evidence:
  - reference: PMID:34101622
    reference_title: "Longitudinal genotype-phenotype analysis in 86 patients with PAX6-related aniridia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nystagmus was recorded in 87.2% of the eyes, and foveal hypoplasia was found in 75%."
    explanation: >
      Quantifies foveal hypoplasia at 75% of 172 eyes, supporting the FREQUENT
      band (80-30%).
- category: Ocular
  name: Nystagmus
  description: >
    Infantile nystagmus, secondary to the congenital sensory deficit imposed by
    foveal hypoplasia. Usually apparent within the first months of life and
    often the sign that brings the child to attention.
  phenotype_term:
    preferred_term: Nystagmus
    term:
      id: HP:0000639
      label: Nystagmus
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:34101622
    reference_title: "Longitudinal genotype-phenotype analysis in 86 patients with PAX6-related aniridia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nystagmus was recorded in 87.2% of the eyes, and foveal hypoplasia was found in 75%."
    explanation: >
      87.2% of eyes places nystagmus in the VERY_FREQUENT band (99-80%).
- category: Ocular
  name: Cataract
  description: >
    Lens opacity, typically presenile and progressive, developing through
    childhood and adolescence. A frequent indication for surgery, though the
    acuity gain is limited by the coexisting foveal hypoplasia.
  phenotype_term:
    preferred_term: Cataract
    term:
      id: HP:0000518
      label: Cataract
    clinical_course: PROGRESSIVE
  frequency: FREQUENT
  evidence:
  - reference: PMID:34101622
    reference_title: "Longitudinal genotype-phenotype analysis in 86 patients with PAX6-related aniridia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cataracts were diagnosed in 70.3%, glaucoma in 20.6%, and ARK in 68.6% of eyes."
    explanation: >
      70.3% of eyes places cataract in the FREQUENT band (80-30%).
- category: Ocular
  name: Aniridia-Associated Keratopathy
  description: >
    Progressive conjunctivalization, vascularization and opacification of the
    cornea arising from limbal stem cell deficiency, advancing from periphery to
    centre over decades.
  phenotype_term:
    preferred_term: Aniridia-associated keratopathy
    term:
      id: HP:0000481
      label: Abnormal cornea morphology
    clinical_course: PROGRESSIVE
  frequency: FREQUENT
  evidence:
  - reference: PMID:34101622
    reference_title: "Longitudinal genotype-phenotype analysis in 86 patients with PAX6-related aniridia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cataracts were diagnosed in 70.3%, glaucoma in 20.6%, and ARK in 68.6% of eyes."
    explanation: >
      68.6% of eyes affected by aniridia-related keratopathy, placing it in the
      FREQUENT band (30-79%). The phenotype is bound to the broad corneal term
      because the 68.6% figure was measured for keratopathy as a whole; binding
      it to a narrower feature such as corneal neovascularization would apply a
      frequency to something this source did not measure.
- category: Ocular
  name: Glaucoma
  description: >
    Secondary glaucoma from a maldeveloped and progressively occluded
    iridocorneal angle, usually of later childhood or adolescent onset rather
    than congenital.
  phenotype_term:
    preferred_term: Glaucoma
    term:
      id: HP:0000501
      label: Glaucoma
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:34101622
    reference_title: "Longitudinal genotype-phenotype analysis in 86 patients with PAX6-related aniridia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cataracts were diagnosed in 70.3%, glaucoma in 20.6%, and ARK in 68.6% of eyes."
    explanation: >
      20.6% of eyes places glaucoma in the OCCASIONAL band (29-5%).
- category: Ocular
  name: Photophobia
  description: >
    Light sensitivity and disabling glare resulting from loss of the iris
    aperture, ranked by patients among the dominant symptoms of the disease.
  phenotype_term:
    preferred_term: Photophobia
    term:
      id: HP:0000613
      label: Photophobia
  evidence:
  - reference: PMID:40892309
    reference_title: "Congenital aniridia: European COST action ANIRIDIA-NET guidelines for diagnosis, management and care."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The main ocular symptoms experienced by those with congenital aniridia are photophobia, glare, low visual acuity, dryness/irritation of the ocular surface and nystagmus."
    explanation: >
      Names photophobia first among the main patient-experienced symptoms. No
      frequency band is asserted because this source reports symptom
      prominence, not a proportion.
- category: Ocular
  name: Reduced Visual Acuity
  description: >
    Congenitally subnormal acuity, structurally determined by foveal hypoplasia
    and not correctable by refraction; further reduced in adulthood by
    keratopathy and cataract.
  phenotype_term:
    preferred_term: Reduced visual acuity
    term:
      id: HP:0007663
      label: Reduced visual acuity
  evidence:
  - reference: PMID:40892309
    reference_title: "Congenital aniridia: European COST action ANIRIDIA-NET guidelines for diagnosis, management and care."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The main ocular symptoms experienced by those with congenital aniridia are photophobia, glare, low visual acuity, dryness/irritation of the ocular surface and nystagmus."
    explanation: >
      Documents low visual acuity as a core feature. Evidence source is OTHER
      because this is a consensus guideline review.
- category: Ocular
  name: Ocular Surface Dryness
  description: >
    Tear film instability and ocular surface irritation, contributing to the
    chronic inflammatory environment in which keratopathy progresses.
  phenotype_term:
    preferred_term: Keratoconjunctivitis sicca
    term:
      id: HP:0001097
      label: Keratoconjunctivitis sicca
  evidence:
  - reference: PMID:40892309
    reference_title: "Congenital aniridia: European COST action ANIRIDIA-NET guidelines for diagnosis, management and care."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The main ocular symptoms experienced by those with congenital aniridia are photophobia, glare, low visual acuity, dryness/irritation of the ocular surface and nystagmus."
    explanation: >
      Names ocular surface dryness and irritation among the main symptoms.
- category: Ocular
  name: Optic Nerve Hypoplasia
  description: >
    A less commonly recognized posterior component of the PAX6 phenotype,
    contributing to visual impairment independently of the foveal and anterior
    segment defects.
  phenotype_term:
    preferred_term: Optic nerve hypoplasia
    term:
      id: HP:0000609
      label: Optic nerve hypoplasia
  evidence:
  - reference: PMID:40892309
    reference_title: "Congenital aniridia: European COST action ANIRIDIA-NET guidelines for diagnosis, management and care."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Other ocular comorbidities are associated with the disease, such as cataract, keratopathy and optic nerve hypoplasia."
    explanation: >
      Lists optic nerve hypoplasia among the recognized ocular comorbidities of
      congenital aniridia.
- category: Renal
  name: Wilms Tumour
  description: >
    Nephroblastoma arising from loss of WT1 in the contiguous 11p13 deletion
    form. Renal ultrasound surveillance is indicated until the deletion
    breakpoints are known to spare WT1.
  subtype: WAGR
  phenotype_term:
    preferred_term: Nephroblastoma
    term:
      id: HP:0002667
      label: Nephroblastoma
  evidence:
  - reference: PMID:33300417
    reference_title: "A rare case of an isolated PAX6 mutation, aniridia, and Wilms tumor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "Aniridia, a pan-ocular disease resulting from iris hypoplasia, is thought to increase the risk for WT development if their genetic alteration spans both the WT1 and the PAX6 genes on 11p13."
    explanation: >
      Ties the tumour risk specifically to deletions spanning WT1, which is what
      restricts this phenotype to the WAGR subtype.
- category: Neurological
  name: Intellectual Disability
  description: >
    Developmental delay and intellectual disability in the contiguous deletion
    form, attributable to loss of additional 11p13 genes rather than to PAX6.
  subtype: WAGR
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:34876316
    reference_title: "Neuropsychological and neurophysiological features of WAGR syndrome: Detailed comprehensive evaluation of a patient with severe intellectual disability and autism spectrum disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Wilms' tumor, aniridia, genitourinary anomalies, and mental retardation (WAGR) syndrome is a contiguous gene deletion syndrome caused by a de novo deletion including the 11p13 region."
    explanation: >
      Establishes intellectual disability as a defining component of the
      contiguous deletion syndrome rather than of PAX6-related aniridia itself.
- category: Endocrine
  name: Type 2 Diabetes Mellitus
  description: >
    An excess of type 2 diabetes has been observed in PAX6-related aniridia
    cohorts, consistent with the role of PAX6 in pancreatic islet development.
    Reported at roughly twice population prevalence in a UK longitudinal series.
  phenotype_term:
    preferred_term: Type II diabetes mellitus
    term:
      id: HP:0005978
      label: Type II diabetes mellitus
  evidence:
  - reference: PMID:34101622
    reference_title: "Longitudinal genotype-phenotype analysis in 86 patients with PAX6-related aniridia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Systemic evaluation identified type 2 diabetes in 12.8% of the study group, which is twice the UK prevalence."
    explanation: >
      Quantifies the excess directly. No frequency band is asserted because the
      claim of interest is the excess over background, not the raw proportion.
genetic:
- name: PAX6
  association: Heterozygous loss-of-function variant or whole-gene deletion
  subtype: Aniridia 1
  notes: >
    Paired box protein 6, the dose-sensitive master regulator of eye development
    at 11p13. Heterozygous loss of function - nonsense, frameshift, splice,
    whole-gene deletion, or disruption of the downstream cis-regulatory enhancer
    within an adjacent gene - causes classic aniridia by haploinsufficiency.
    Missense variants that retain partial function give milder phenotypes,
    including the variant presentations formerly called autosomal dominant
    keratitis.
  gene_term:
    preferred_term: PAX6
    term:
      id: hgnc:8620
      label: PAX6
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:24138039
    reference_title: "A review of the clinical and genetic aspects of aniridia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Variants of aniridia, which include a condition previously referred to as autosomal dominant keratitis, are likely due to PAX6 mutations that lead to partial loss of PAX6 function."
    explanation: >
      Supports the allelic-series claim that residual PAX6 function produces
      milder, sometimes differently named phenotypes.
- name: PAX6 downstream regulatory region
  association: Deletion of cis-regulatory DNA with an intact PAX6 transcription unit
  relationship_type: CAUSATIVE
  subtype: Aniridia 2
  affected_regions:
  - name: PAX6 downstream regulatory region (DRR)
    chromosomal_region: 11p13
    regulatory_element_type: ENHANCER
    within_gene:
      preferred_term: ELP4
      term:
        id: hgnc:1171
        label: ELP4
    description: PAX6-specific control elements within ELP4 introns, downstream of their target gene.
  notes: >-
    This regional association complements the PAX6 gene association. ELP4 is
    the intronic host of the DRR, not a substitute causal-gene annotation.
    The human deletions can extend beyond the named regulatory region.
  variants:
  - name: Lauderdale et al. PAX6 downstream deletions (cases 1 and 2)
    variant_type: deletion
    genomic_contexts:
    - intron
    gene:
      preferred_term: ELP4
      term:
        id: hgnc:1171
        label: ELP4
    regulatory_target_gene:
      preferred_term: PAX6
      term:
        id: hgnc:8620
        label: PAX6
    affected_regions:
    - name: PAX6 downstream regulatory region (DRR)
      chromosomal_region: 11p13
      regulatory_element_type: ENHANCER
      within_gene:
        preferred_term: ELP4
        term:
          id: hgnc:1171
          label: ELP4
      description: The affected enhancer cluster is one component of the larger downstream deletions.
    description: >-
      Two de novo submicroscopic deletions in the sporadic aniridia cases
      reported by Lauderdale et al. retain PAX6 and lie more than 11 kb beyond
      its 3' end. Their expression defect was assayed in human-mouse somatic-cell
      hybrids. These are two distinct alleles, not one recurrent deletion;
      the regional annotation does not assign common nucleotide breakpoints.
    functional_effects:
    - function: PAX6 cis-regulatory control
      regulatory_element_type: ENHANCER
      regulatory_mechanism: Deletion of downstream positive regulatory elements
      description: >-
        PAX6 transcription was absent from the deletion-bearing chromosome in
        somatic-cell hybrids. This assay does not establish all-tissue loss
        of expression in the patients or isolate the contribution of every
        individual enhancer within the deleted region.
    evidence:
    - reference: PMID:11087823
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We report two submicroscopic de novo deletions of 11p13 that cause
        aniridia but are located >11 kb from the 3' end of PAX6.
      explanation: The two sporadic patient deletions preserve the PAX6 transcription unit.
    - reference: PMID:11087823
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        PAX6 is transcribed only from the normal allele but not from the deleted
        chromosome 11 homolog.
      explanation: Allele-specific transcription was tested in human-mouse retinoblastoma somatic-cell hybrids.
    - reference: PMID:17014839
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: BACKGROUND
      snippet: >-
        Analysis of the region beyond this breakpoint using YAC transgenic mice,
        DNaseI hypersensitivity mapping and reporter transgenic assays revealed
        the presence of several putative cis-regulatory elements, including ones
        driving expression in lens and retina (Kleinjan et al., 2001). These
        elements reside within introns of the adjacent, ubiquitously expressed
        ELP4 gene, but are nevertheless thought to be PAX6-specific long-range
        control elements (Kleinjan et al., 2002).
      explanation: >-
        Summarizes earlier transgenic-mouse enhancer mapping and the human
        locus annotation supporting ELP4 as the DRR host, separate from PAX6
        as the regulatory target. It does not resolve these patients'
        deletion breakpoints.
  evidence:
  - reference: PMID:11087823
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We report two submicroscopic de novo deletions of 11p13 that cause aniridia
      but are located >11 kb from the 3' end of PAX6.
    explanation: Supports aniridia caused by downstream deletions rather than PAX6 coding loss.
  - reference: PMID:17014839
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: BACKGROUND
    snippet: >-
      Analysis of the region beyond this breakpoint using YAC transgenic mice,
      DNaseI hypersensitivity mapping and reporter transgenic assays revealed
      the presence of several putative cis-regulatory elements, including ones
      driving expression in lens and retina (Kleinjan et al., 2001). These
      elements reside within introns of the adjacent, ubiquitously expressed
      ELP4 gene, but are nevertheless thought to be PAX6-specific long-range
      control elements (Kleinjan et al., 2002).
    explanation: >-
      Background description of transgenic-mouse enhancer mapping and the
      human locus places the named DRR elements within ELP4 introns, without
      making ELP4 the regulatory target.
- name: WT1
  association: Heterozygous loss within a contiguous 11p13 deletion
  notes: >
    Wilms tumour 1, immediately adjacent to PAX6 at 11p13. It is not a cause of
    aniridia; its loss in a contiguous deletion is what converts isolated
    aniridia into WAGR syndrome and creates the nephroblastoma risk.
  subtype: WAGR
  gene_term:
    preferred_term: WT1
    term:
      id: hgnc:12796
      label: WT1
  relationship_type: CAUSATIVE
  evidence:
  - reference: PMID:33300417
    reference_title: "A rare case of an isolated PAX6 mutation, aniridia, and Wilms tumor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "WAGR results from a contiguous gene deletion within the 11p13 region, encompassing the WT1 gene, often responsible for WT development, and the PAX6 gene, responsible for aniridia."
    explanation: >
      Assigns the tumour risk to WT1 and the ocular phenotype to PAX6 within one
      deletion, which is the basis for separating this gene's contribution to
      the WAGR subtype.
- name: TRIM44
  association: Heterozygous missense variant acting in trans on PAX6 expression
  relationship_type: UNKNOWN
  subtype: Aniridia 3
  gene_term:
    preferred_term: TRIM44
    term:
      id: hgnc:19016
      label: TRIM44
  notes: >-
    TRIM family member 44, also at 11p13, where it was first mapped while
    searching the WAGR region. Reported in seven affected members of a single
    four-generation Chinese family, carrying a heterozygous missense variant
    c.463G>A (p.Gly155Arg) in exon 1; overexpressed mutant TRIM44 lowered PAX6 in
    cultured human lens epithelial cells more than the wild-type protein did.
    Unlike the regulatory deletions hosted in ELP4 introns, the lesion is in
    TRIM44 coding sequence and the effect on PAX6 is in trans. Typed UNKNOWN
    rather than CAUSATIVE because ClinGen grades the relationship Limited on one
    published study.
  evidence:
  - reference: CGGV:assertion_c03ad7e1-74ea-4c47-b372-5beb8fbf4e97-2023-03-16T160000.000Z
    reference_title: "TRIM44 / aniridia 3 (Limited)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TRIM44 was mapped to 11p13 in a study (PMID:10568747) searching for genes in a region of chromosome 11 associated with WAGR syndrome (Wilms tumor-aniridia-genital anomalies-retardation)."
    explanation: >-
      Source for the locus and for how the gene came to attention in aniridia.
  - reference: CGGV:assertion_c03ad7e1-74ea-4c47-b372-5beb8fbf4e97-2023-03-16T160000.000Z
    reference_title: "TRIM44 / aniridia 3 (Limited)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "There is only one published study reporting this gene-disease association to date, so there is limited but suggestive evidence to support the relationship between TRIM44 and ocular dysgenesis caused by defects in PAX6 regulation."
    explanation: >-
      ClinGen's own statement of how thin the evidence base is, which is the
      reason for the UNKNOWN typing on this row.
  - reference: CGGV:assertion_c03ad7e1-74ea-4c47-b372-5beb8fbf4e97-2023-03-16T160000.000Z
    reference_title: "TRIM44 / aniridia 3 (Limited)"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In 7 affected members of 4-generation Chinese family with aniridia linked to chromosome 11p13, Zhang et al. (PMID: 26394807) identified a heterozygous missense variant, c.463G>A (p.Gly155Arg), in exon 1 of TRIM44"
    explanation: >-
      The single pedigree behind this row, with the variant ClinGen scored.
  - reference: PMID:26394807
    reference_title: Variants in TRIM44 Cause Aniridia by Impairing PAX6 Expression.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We conclude that inhibition of PAX6 expression by mutant TRIM44 is a novel pathogenic mechanism for aniridia."
    explanation: >-
      The report's own conclusion, resting on the lens-epithelial-cell assay
      rather than on a patient measurement.
treatments:
- name: Topical Intraocular Pressure-Lowering Pharmacotherapy
  description: >
    First-line medical management of the secondary glaucoma, using topical
    agents such as prostaglandin analogues, beta-blockers and carbonic anhydrase
    inhibitors. Glaucoma in aniridia responds less predictably than primary
    open-angle glaucoma because the outflow pathway is structurally maldeveloped
    rather than merely obstructed, so lifelong pressure surveillance is required
    from diagnosis.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: prostaglandin analogue (e.g. latanoprost)
      term:
        id: CHEBI:6384
        label: latanoprost
    - preferred_term: topical beta-blocker (e.g. timolol)
      term:
        id: CHEBI:39465
        label: timolol
  target_mechanisms:
  - target: Maldeveloped Aqueous Outflow and Secondary Glaucoma
    treatment_effect: INHIBITS
    description: >
      Lowering intraocular pressure targets the consequence of the maldeveloped
      outflow pathway; it does not correct the developmental defect, which is
      why control is imperfect and surveillance permanent.
  evidence:
  - reference: PMID:40892309
    reference_title: "Congenital aniridia: European COST action ANIRIDIA-NET guidelines for diagnosis, management and care."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Management and follow-up of patients with congenital aniridia can be challenging due to the lack of effective therapeutic options and the complexity of ocular manifestations and outcomes."
    explanation: >
      The European guideline states plainly that effective therapeutic options
      are lacking. Marked PARTIAL because it supports the management framing
      while explicitly not asserting efficacy.
- name: Glaucoma Surgery for Medically Uncontrolled Intraocular Pressure
  description: >
    Angle or filtering surgery, or a glaucoma drainage device, when topical
    therapy fails to control pressure. Separated from the medical arm because it
    is a different modality with a different risk profile, and because
    surgically naive eyes in the longitudinal cohort maintained better visual
    acuity - so the decision to operate is itself consequential rather than a
    simple escalation.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Ophthalmologic Surgical Procedure
    term:
      id: NCIT:C15331
      label: Ophthalmologic Surgical Procedure
  target_mechanisms:
  - target: Maldeveloped Aqueous Outflow and Secondary Glaucoma
    treatment_effect: INHIBITS
    description: >
      Surgical drainage bypasses the maldeveloped outflow pathway rather than
      correcting it, which is why pressure control remains imperfect and
      surveillance permanent.
  evidence:
  - reference: PMID:34101622
    reference_title: "Longitudinal genotype-phenotype analysis in 86 patients with PAX6-related aniridia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prevalence, age of diagnosis and surgical intervention, and need for surgical intervention varied among mutation groups."
    explanation: >
      Establishes that surgical intervention is part of the management of this
      disease and that the need for it is genotype-dependent. Marked PARTIAL
      because the cohort reports variation in surgical need rather than
      demonstrating surgical efficacy.

- name: Limbal Stem Cell Replacement and Keratoprosthesis
  description: >
    Surgical management of advanced keratopathy. Because the corneal opacity is
    driven by a deficient stem cell niche rather than by the cornea itself,
    plain penetrating keratoplasty is re-conjunctivalized; the options are to
    replace the limbal stem cells by keratolimbal allograft, with or without
    subsequent keratoplasty, or to bypass the surface entirely with a Boston
    type 1 keratoprosthesis.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Ophthalmologic Surgical Procedure
    term:
      id: NCIT:C15331
      label: Ophthalmologic Surgical Procedure
  target_mechanisms:
  - target: Limbal Stem Cell Deficiency
    treatment_effect: RESTORES
    description: >
      Keratolimbal allograft aims to restore the deficient stem cell
      compartment itself, which is why it is directed at this node rather than
      at the keratopathy it produces.
    evidence:
    - reference: PMID:24138039
      reference_title: "A review of the clinical and genetic aspects of aniridia."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: "The current treatments for AAK are to replace the limbal stem cells through keratolimbal allograft (KLAL) with or without subsequent keratoplasty for visual rehabilitation, or to implant a Boston type 1 keratoprosthesis."
      explanation: >
        States that the therapeutic target is the limbal stem cell compartment,
        supporting the mechanism link this treatment declares.
  evidence:
  - reference: PMID:24138039
    reference_title: "A review of the clinical and genetic aspects of aniridia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The current treatments for AAK are to replace the limbal stem cells through keratolimbal allograft (KLAL) with or without subsequent keratoplasty for visual rehabilitation, or to implant a Boston type 1 keratoprosthesis."
    explanation: >
      Enumerates the current surgical options for aniridia-associated
      keratopathy. Evidence source is OTHER because this is a review.
- name: Renal Tumour Surveillance in Contiguous Deletion Aniridia
  description: >
    Serial renal ultrasonography for children with sporadic aniridia until the
    molecular lesion is shown not to involve WT1. This is the one intervention
    in aniridia that alters mortality rather than vision, and it is why
    molecular diagnosis in a sporadic case is urgent. Applies to the WAGR
    (contiguous 11p13 deletion) subtype.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:33300417
    reference_title: "A rare case of an isolated PAX6 mutation, aniridia, and Wilms tumor."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Isolated mutations in PAX6 previously have not been associated with increased risk of WT development case raises the question of if surveillance for WT should be continued in patients with aniridia with an isolated PAX6 mutation identified."
    explanation: >
      Supports surveillance as the standard for deletion-associated aniridia
      while documenting the open question this case raises about whether an
      identified isolated PAX6 variant is sufficient to stop it. Marked PARTIAL
      because it is a single case that unsettles rather than confirms practice.
- name: Genetic Counselling and Molecular Diagnosis
  description: >
    Determination of the causative lesion - intragenic PAX6 variant versus
    contiguous 11p13 deletion - drives both tumour surveillance and
    reproductive counselling for a dominant condition with high penetrance and
    a substantial de novo rate.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:24138039
    reference_title: "A review of the clinical and genetic aspects of aniridia."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Classic aniridia can be genetically defined as the presence of a PAX6 gene deletion or loss-of-function mutation that results in haploinsufficiency."
    explanation: >
      Supports the genetic definition on which counselling and the
      deletion-versus-intragenic distinction rest. Evidence source is OTHER
      because this is a review.
experimental_models:
- name: Patient-derived iPSC corneal organoid model of aniridia-associated keratopathy
  experimental_model_type: ORGANOID
  description: >
    Three-dimensional corneal organoids differentiated from induced pluripotent
    stem cells of aniridia patients, generating corneal epithelial-like cells in
    a self-assembled tissue that reproduces the native corneal microenvironment.
    Provides a human genotype-matched system for the limbal arm of the disease,
    complementing the Pax6-heterozygous mouse.
  publication: PMID:42612147
  modeled_mechanisms:
  - target: Limbal Stem Cell Deficiency
    relationship: MEASURES
    fidelity: MODERATE
    description: >
      The organoid provides a human, patient-genotype platform for interrogating
      corneal epithelial differentiation, which is the process this node asserts
      is defective.
    limitations: >
      Organoids lack the limbal niche vasculature, tear film, innervation and
      chronic inflammatory environment in which aniridia-associated keratopathy
      actually progresses, so they can model the differentiation defect but not
      the decades-long clinical progression it drives.
    evidence:
    - reference: PMID:42612147
      reference_title: "Patient-Specific iPSC-Derived Cornea Organoids for Investigating Aniridia-Associated Corneal Disorders."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Our protocol involves the stepwise differentiation of iPSCs into corneal epithelial-like cells within self-assembled three-dimensional organoids, which mimic the native corneal microenvironment."
      explanation: >
        Establishes that the model produces the cell type whose differentiation
        this mechanism node concerns.
animal_models:
- name: Pax6 heterozygous mouse
  species: Mouse
  genotype: Pax6 heterozygous (Pax6+/-)
  description: >
    The standard genetic model of aniridia-associated keratopathy, matching the
    human haploinsufficient genotype. Single-cell RNA sequencing of its cornea
    and limbus identified an accumulation of quiescent limbal stem cell-like and
    early transit-amplifying cells that fail to commit to a corneal epithelial
    fate.
  publication: PMID:41590604
  modeled_mechanisms:
  - target: Limbal Stem Cell Deficiency
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >
      Reproduces the human haploinsufficient genotype and the corneal
      stem-cell-commitment defect, in the tissue where the human disease
      progresses.
    limitations: >
      Mouse and human corneal limbal anatomy differ, and the mouse does not
      develop the decades-long conjunctivalization and vascularization that
      define the human keratopathy endpoint.
    readouts:
    - name: Expression of corneal epithelial fate and differentiation genes in early transit-amplifying cells
      target: Limbal Stem Cell Deficiency
      direction: DECREASED
      interpretation: >
        Molecular correlate of the failed commitment this node asserts.
      evidence:
      - reference: PMID:41590604
        reference_title: "PAX6 Deficiency Compromises the Ability of Limbal Epithelial Stem Cells to Properly Differentiate Into Mature Corneal Epithelial Cells."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "The Pax6 deficiency inhibited the expression of genes involved in cell proliferation in the eTAC-like cluster as well as the expression of genes related to corneal epithelial cell fate and differentiation compared with WT mice."
        explanation: >
          Reports the measurement and its direction directly.
    evidence:
    - reference: PMID:41590604
      reference_title: "PAX6 Deficiency Compromises the Ability of Limbal Epithelial Stem Cells to Properly Differentiate Into Mature Corneal Epithelial Cells."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Aniridia, driven by PAX6 mutations, causes aniridia-associated keratopathy (AAK), a progressive condition linked to limbal stem cell deficiency."
      explanation: >
        States the human mechanism the model is used to interrogate, supporting
        treating this model as informative for this node.
discussions:
- discussion_id: aniridia_wt_surveillance_isolated_pax6
  kind: KNOWLEDGE_GAP
  prompt: >-
    Can renal tumour surveillance be safely discontinued in a child with
    sporadic aniridia once an intragenic PAX6 variant has been identified and a
    WT1-spanning deletion excluded?
  attaches_to:
  - "pathophysiology#PAX6 Haploinsufficiency"
  rationale: >-
    Current practice rests on the assumption that Wilms tumour risk in aniridia
    is carried entirely by WT1 loss in the contiguous deletion, so identifying
    an intragenic PAX6 variant should release the child from years of
    ultrasound surveillance. A reported case of Wilms tumour in a patient with
    aniridia due to a heterozygous PAX6 nonsense variant and no other
    identifiable germline driver directly unsettles that assumption. Because
    the decision trades a real surveillance burden against a lethal but
    treatable malignancy, and because it is the only mortality-relevant decision
    in the management of aniridia, the question is worth marking explicitly
    rather than treating as settled.
  proposed_experiments:
  - experiment_id: aniridia_intragenic_pax6_tumour_registry
    name: Registry-scale tumour incidence in molecularly defined intragenic PAX6 aniridia
    description: >
      Pool international aniridia registries to estimate Wilms tumour incidence
      specifically among patients with confirmed intragenic PAX6 variants and
      breakpoint-mapped exclusion of WT1 involvement, with power to detect an
      excess over population background.
references:
- reference: PMID:20301534
  title: PAX6 Aniridia Syndrome.
  tags:
  - GeneReviews
  findings: []
- reference: PMID:41818601
  title: WAGR Spectrum Disorder.
  tags:
  - GeneReviews
  findings: []

📚

References & Deep Research

References

2

PMID:20301534

PAX6 Aniridia Syndrome.

No top-level findings curated for this source.

PMID:41818601

WAGR Spectrum Disorder.

No top-level findings curated for this source.

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Experimental Models

Animal Models

Source YAML

References & Deep Research

References